TARGET DOSE: 300 mg to 450 mg per day, in divided doses, by the end of 2 weeks.

Titration: Increase the total daily dosage in increments of 25 mg to 50 mg per day, if well-tolerated.

Use cautious titration and divided dosage schedule (2.2, 5.3).

STARTING DOSE: 12.5 mg once daily or twice daily (2.2).

KNOWLEDGE SERIOUS HYPERSENSITIVITY TO CLOzapine OR ANY OTHER COMPONENT OF CLOzapine

- Treatment-resistant schizophrenia. Efficacy was established in an active-controlled study (1.2, 14.2).

CLOzapine tablets are an atypical antipsychotic indicated for:

- Schizophrenia and schizoaffective disorder, for treatment of co-morbid conditions (5.11).
- Efficacy was established in an active-controlled study (1.2, 14.2).

Increased Mortality in Elderly Patients with Dementia-Related Psychosis:

CLOzapine is not approved for this condition (5.7).

ADVERSE REACTIONS

Most common adverse reactions (~5%) were: CNS reactions (sedation, dizziness/vertigo, headache, and tremor); cardiovascular reactions (tachycardia, hypotension, and syncope); autonomic nervous system reactions (hypersalivation, sweating, dry mouth, and visual disturbances); gastrointestinal reactions (constipation and nausea); and fever (6.1).

To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals USA, Inc. at 1-866-832-9537 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

- Concomitant use of Strong CYP1A2 Inhibitors: Reduce clozapine dose to one-third when coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, enoxacin) (2.6, 7.1).

- Use with Extreme Caution: CYP3A4 Inducers (e.g., carbamazepine) are discontinued (2.6, 7.1).

USE IN SPECIFIC POPULATIONS

- Nursing Mothers: Discontinue drug or discontinue nursing, taking into consideration importance of drug to mother (8.3).

See 17 for PATIENT COUNSELING INFORMATION

Revised: 03/2017
12.1 Mechanism of Action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

14.1 Treatment-Resistant Schizophrenia

14.2 Recurrent Suicidal Behavior in Schizophrenia or Schizoaffective Disorder

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

16.2 Storage and Handling

17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed.

2 DOSAGE AND ADMINISTRATION

2.1 Required Laboratory Testing Prior to Initiation and During Therapy

2.2 Dosing Information

2.3 Maintenance Treatment

2.4 Discontinuation of Treatment

Method of treatment discontinuation will vary depending on the patient’s last ANC:
- • See Tables 2 or 3 for appropriate ANC monitoring based on the level of neutrope-

2.5 Re-Initiation of Treatment

When restarting clozapine tablets in patients who have discontinued clozapine tabs-

3 NONCLINICAL TOXICOLOGY

3.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

3.2 Toxicity to Reproduction

Table 1: Dose Adjustment in Patients Taking Concomitant Medications

<table>
<thead>
<tr>
<th>Co-medications</th>
<th>Scenarios</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initiating clozapine tablets while taking a co-medication</td>
<td>Adding a co-medication while taking clozapine tablets</td>
</tr>
<tr>
<td>Strong CYP1A2 Inhibitors</td>
<td>Use one-third of the clozapine tablets dose.</td>
</tr>
<tr>
<td>Moderate or Weak CYP1A2 Inhibitors</td>
<td>Monitor for adverse reactions. Consider reducing the clozapine tablets dose if necessary.</td>
</tr>
</tbody>
</table>

CYP2D6 or CYP3A4 Inhibitors

Dose adjustments may be necessary in patients with concomitant use of: strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, or enoxacin); moderate or weak CYP1A2 inhibitors (e.g., oral contraceptives, or caffeine); CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline); CYP3A4 inducers (e.g., phenytoin, carbamazepine, St. John’s wort, or rifampin); or CYP1A2 inducers (e.g., tobacco use) (Table 1) [see Drug Interactions (7)].
CLOZAPINE TABLETS

2.7 Renal or Hepatic Impairment or CYP2D6 Poor Metabolizers

It may be necessary to reduce the clozapine tablets dose in patients with significant renal or hepatic impairment, or in CYP2D6 poor metabolizers [see Use in Specific Populations (8.6, 8.7)].

3 DOSAGE FORMS AND STRENGTHS

Clozapine tablets are available as 25 mg, 50 mg, 100 mg, and 200 mg pale-yellow tablets with a score on one side.

4 CONTRAINDICATIONS

4.1 Hypersensitivity

Clozapine tablets are contraindicated in patients with a history of serious hypersensitivity to clozapine (e.g., photosensitivity, vasculitis, erythema multiforme, or Stevens-Johnson Syndrome) or any other component of clozapine tablets [see Adverse Reactions (6.1)].

5 WARNINGS AND PRECAUTIONS

5.1 Severe Neutropenia

**Background**

Clozapine can cause neutropenia (a low absolute neutrophil count (ANC)), defined as a reduction below pre-treatment normal levels of blood neutrophils. The ANC is usually available as a component of the complete blood count (CBC), including differential, and is more relevant to drug-induced neutropenia than is the white blood cell (WBC) count. The ANC may also be calculated using the following formula:

\[
\text{ANC} = \text{Total WBC count multiplied by the total percentage of neutrophils obtained from the differential (neutrophils "segs" plus neutrophil "bands" \() \]

Other granulocytes (basophils and eosinophils) contribute minimally to neutropenia and their measurement is not necessary [see Adverse Reactions (6.2)]. Neutropenia may be mild, moderate, or severe (see Tables 2 and 3). To improve and standardize understanding, “severe neutropenia” replaces the previous terms severe leukopenia, severe granulocytopenia, or agranulocytosis. Severe neutropenia, ANC less than (<) 500/μL, occurs in a small percentage of patients taking clozapine and is associated with an increase in the risk of serious and potentially fatal infections. Risk of neutropenia appears greatest during the first 18 weeks on treatment and then declines. The mechanism by which clozapine causes neutropenia is unknown and is not dose-dependent.

Two separate management algorithms are provided below, the first for patients in the general population, and the second for patients identified to have baseline neutropenia.

**Clozapine Treatment and Monitoring in the General Patient Population (see Table 2)**

Obtain a CBC, including the ANC value, prior to initiating treatment with clozapine to ensure the presence of a normal baseline neutrophil count (equal to or greater than 1500/μL) and to permit later comparisons. Patients in the general population with an ANC equal to or greater than (≥)1500/μL are considered within normal range (Table 2) and are eligible to initiate treatment. Weekly ANC monitoring is required for all patients during the first 6 months of treatment. If a patient’s ANC remains equal to or greater than 1500/μL for the first 6 months of treatment, monitoring frequency may be reduced to every 2 weeks for the next 6 months. If the ANC remains equal to or greater than 1500/μL for the second 6 months of continuous therapy, ANC monitoring frequency may be reduced to once every 4 weeks thereafter.

**Table 2: Clozapine Treatment Recommendations Based on Absolute Neutrophil Count (ANC) Monitoring for the General Patient Population**

<table>
<thead>
<tr>
<th>ANC Level</th>
<th>Treatment Recommendations</th>
<th>ANC Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal range (≥1500/μL)</td>
<td>Initiate treatment</td>
<td>Weekly from initiation to 6 months</td>
</tr>
<tr>
<td></td>
<td>If treatment interrupted:</td>
<td>Every 2 weeks from 6 to 12 months</td>
</tr>
<tr>
<td></td>
<td>- &lt; 30 days, continue monitoring as before</td>
<td>Monthly after 12 months</td>
</tr>
<tr>
<td></td>
<td>- ≥ 30 days, monitor as if new patient</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Discontinuation for reasons other than neutropenia</td>
<td>See Section 2.4</td>
</tr>
</tbody>
</table>

**Mild Neutropenia (1000 to 1499/μL)**

<table>
<thead>
<tr>
<th>Treatment Recommendations</th>
<th>ANC Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continue treatment</td>
<td>Three times weekly until ANC ≥1500/μL</td>
</tr>
<tr>
<td></td>
<td>Once ANC ≥1500/μL, return to patient’s last “Normal Range” ANC monitoring interval</td>
</tr>
</tbody>
</table>

**Table 3: Patients with Benign Ethnic Neutropenia (BEN); Clozapine Treatment Recommendations Based on Absolute Neutrophil Count (ANC) Monitoring**

<table>
<thead>
<tr>
<th>ANC Level</th>
<th>Treatment Recommendations</th>
<th>ANC Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal BEN Range (Established ANC baseline ≥1000/μL)</td>
<td>Obtain at least two baseline ANC levels before initiating treatment</td>
<td>Weekly from initiation to 6 months</td>
</tr>
<tr>
<td></td>
<td>If treatment interrupted:</td>
<td>Every 2 weeks from 6 to 12 months</td>
</tr>
<tr>
<td></td>
<td>- &lt; 30 days, continue monitoring as before</td>
<td>Monthly after 12 months</td>
</tr>
<tr>
<td></td>
<td>- ≥ 30 days, monitor as if new patient</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Discontinuation of treatment for reasons other than neutropenia</td>
<td>See Section 2.4</td>
</tr>
</tbody>
</table>

**BEN Neutropenia 500 to 999/μL**

<table>
<thead>
<tr>
<th>Treatment Recommendations</th>
<th>ANC Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recommend hematology consultation</td>
<td>Three times weekly until ANC ≥1000/μL</td>
</tr>
<tr>
<td>Continue treatment</td>
<td>Once ANC ≥1000/μL or at patient’s known baseline</td>
</tr>
</tbody>
</table>

**Severe Neutropenia (less than 500/μL)**

<table>
<thead>
<tr>
<th>Treatment Recommendations</th>
<th>ANC Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recommend hematology consultation</td>
<td>Daily until ANC ≥1500/μL</td>
</tr>
<tr>
<td>Interrupt treatment for suspected clozapine-induced neutropenia</td>
<td>Once ANC ≥1500/μL, check ANC weekly for 4 weeks, then return to patient’s last “Normal Range” ANC monitoring interval</td>
</tr>
<tr>
<td>Do not rechallenge unless prescriber determines benefits outweigh risks</td>
<td>If patient rechallenged, resume treatment as a new patient under “Normal Range” monitoring once ANC ≥1500/μL</td>
</tr>
</tbody>
</table>

1. Confirm all initial reports of ANC less than 1500/μL with a repeat ANC measurement within 24 Hours
2. If clinically appropriate
CLOZAPINE TABLETS

5.6 Myocarditis, Cardiomyopathy and Mitral Valve Incompetence

Myocarditis and cardiomyopathy have occurred with the use of clozapine. These reactions can be fatal. Discontinue clozapine and obtain a cardiac evaluation upon suspicion of myocarditis or cardiomyopathy. Generally, patients with a history of clozapine-associated myocarditis or cardiomyopathy should not be rechallenged with clozapine. However, if the benefit of clozapine treatment is judged to outweigh the potential risks of recurrence of myocarditis or cardiomyopathy, the clinician may consider rechallenge with clozapine consultation with a cardiologist, after a complete cardiac evaluation, and under close monitoring.

Consider the possibility of myocarditis or cardiomyopathy in patients receiving clozapine who present with chest dyspnea, persistent tachycardia at rest, palpitations, fever, flu-like symptoms, hypotension, other signs or symptoms of heart failure, or electrocardiographic findings (low voltages, ST-T abnormalities, arrhythmias, right axis deviation, and poor R wave progression). Myocarditis most frequently presents within the first 2 months of clozapine treatment. Symptoms of cardiomyopathy may include cardiomegaly and congestive heart failure, which may occur later than cardiomyopathy, which may occur later than myocarditis. In rare cases, electrocardiographic findings suggestive of myocarditis, cardiomyopathy, or both may be present when diastolic filling pressures are normal. Cardiomyopathy may occur beyond the first 2 months of treatment. However, myocarditis and cardiomyopathy can occur at any period during treatment with clozapine. It is common for nonspecific flu-like symptoms such as malaise, myalgia, pleuritic chest pain, and low-grade fevers to precede more overt signs of heart failure. Typical laboratory findings include elevated troponin I or T, and can resolve without intervention. There are reports of successful rechallenge, often after treatment of patients with dementia-related psychosis [see Boxed Warning].

5.7 Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at risk of death from cardiovascular and/or cerebrovascular reactions. In one 10-week trial of elderly patients with dementia-related psychosis, 12 patients (4.1%) taking placebo died as compared to 5 patients (1.5%) treated with clozapine. The difference in death rate between treated and placebo groups was significant (P=0.026).

Clozapine REMS Program

Clozapine is only available through a restricted program under a REMS called the Clozapine REMS Program because of the risk of severe neutropenia. Notable requirements of the Clozapine REMS Program include:

- Healthcare professionals who prescribe clozapine must be certified with the program by enrolling and completing training.
- Pharmacies dispensing clozapine must be certified with the program by enrolling and completing training.
- Healthcare professionals who prescribe clozapine must be certified with the program by enrolling and completing training.
- Patients who receive clozapine must be monitored by the program and have their blood cell counts measured over a 5-day period after the first dose and at least weekly thereafter.
- Cardiologists must be consulted to evaluate patients with suspected cardiomyopathy or myocarditis.
- Cardiologists must be consulted to evaluate patients with suspected cardiomyopathy or myocarditis.

Further information is available at www.clozapinerems.com or 1-844-267-8678.

5.8 Eosinophilia

Eosinophilia, defined as a blood eosinophil count of greater than 700/μL, has occurred with clozapine treatment. In clinical trials, approximately 1% of patients developed eosinophilia. Clozapine-related eosinophilia usually occurs during the first month of treatment. In some patients, it has been associated with myocarditis, pancreatitis, hepatitis, colitis, and nephritis. Such organ involvement could be consistent with a specific treatment–drug adverse reaction known as drug induced hypersensitivity syndrome (DRESS), also known as acute generalized exanthematous pustulosis (AGEP), toxic epidermal necrolysis (TEN), or erythema multiforme (EM). If a cause of eosinophilia unrelated to clozapine is identified (e.g., asthma, allergies, collagen vascular disease, parasitic infections, and specific neoplasms), treat the underlying cause and continue clozapine.

Clonazepine-related eosinophilia has also occurred in the absence of organ involvement and the eosinophil count normalizes after discontinuation of clozapine, without recurrence of eosinophilia. In the absence of organ involvement, continue clozapine under careful monitoring. If the total eosinophil count continues to increase over several weeks in the absence of systemic disease, the decision to interrupt clozapine therapy and rechallenge after discontinuation of clozapine should be based on the overall clinical assessment, in consultation with an internist or hematologist.

5.9 QT Interval Prolongation

QT prolongation, Torsade de Pointes and other life-threatening ventricular arrhythmias, cardiac arrest, and sudden death have occurred with clozapine treatment. When prescribing clozapine, consider the presence of additional risk factors for QT prolongation and serious cardiovascular reactions. Conditions that increase these risks include the following: history of QT prolongation, long QT syndrome, family history of long QT syndrome or sudden cardiac death, significant cardiac arrhythmia, recent myocardial infarction, uncompensated heart failure, treatment with other medications that cause QT prolongation, treatment with medications that inhibit the metabolism of clozapine, and electrolyte abnormalities.

Prior to initiating treatment with clozapine, perform a careful physical examination, medical history, and concomitant medication history. Consider obtaining a baseline ECG and serum chemistry panel. Correct electrolyte abnormalities. Discontinue clozapine if the QTc interval exceeds 500 msec. If patients experience symptoms consistent with Torsades de Pointes, or other arrhythmias (e.g., syncope, presyncope, dizziness, or palpitations), obtain a cardiac evaluation and discontinue clozapine.
5.10 Metabolic Changes

Atypical antipsychotic drugs, including clozapine have been associated with metabolic changes that can increase cardiovascular and cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain. While atypical antipsychotic drugs may produce some metabolic changes, each drug in the class has its own specific risk profile.

Hyperglycemia and Diabetes Mellitus

Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar nonketotic coma or death, has been reported in patients treated with atypical antipsychotics including clozapine. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse reactions is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent, hyperglycemia-related adverse reactions in patients treated with the atypical antipsychotics. Precise risk estimates for hyperglycemia-related adverse reactions in patients treated with atypical antipsychotics are not available.

Patients with an established diagnosis of diabetes mellitus who are started on clozapine should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

In a pooled data analysis of 8 studies in adult subjects with schizophrenia, the mean changes in fasting glucose concentration in the clozapine and chlorpromazine groups were similar and comparable to baseline levels, as illustrated in Table 4. The clozapine doses were 100 to 900 mg per day (mean modal dose: 512 mg per day). The maximum chlorpromazine dose was 1800 mg per day (mean modal dose: 1029 mg per day). The median duration of exposure was 42 days for clozapine and chlorpromazine.

Table 4: Categorical Changes in Fasting Glucose Level in Studies in Adult Subjects with Schizophrenia

<table>
<thead>
<tr>
<th>Laboratory Parameter</th>
<th>Category Change (at least once) from baseline</th>
<th>Treatment Arm</th>
<th>N</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting Glucose</td>
<td>Normal (&lt; 100 mg/dL) to High (≥ 126 mg/dL)</td>
<td>Clozapine</td>
<td>198</td>
<td>53 (27)</td>
</tr>
<tr>
<td></td>
<td>High (≥ 126 mg/dL) to Normal (&lt; 100 mg/dL)</td>
<td>Chlorpromazine</td>
<td>135</td>
<td>14 (10)</td>
</tr>
<tr>
<td></td>
<td>Borderline (100 to 125 mg/dL) to High (≥ 126 mg/dL)</td>
<td>Clozapine</td>
<td>57</td>
<td>24 (42)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chlorpromazine</td>
<td>43</td>
<td>13 (28)</td>
</tr>
</tbody>
</table>

Dyslipidemia

Undesirable alterations in lipids have occurred in patients treated with atypical antipsychotics, including clozapine. Clinical monitoring, including baseline and periodic follow-up lipid evaluations in patients using clozapine, is recommended.

In a pooled data analysis of 10 studies in adult subjects with schizophrenia, clozapine treatment was associated with increases in serum total cholesterol. No data were collected on LDL and HDL cholesterol. The mean increase in total cholesterol was 13 mg/dL in the clozapine group and 15 mg/dL in the chlorpromazine group. In a pooled data analysis of 2 studies in adult subjects with schizophrenia, clozapine treatment was associated with increases in fasting serum triglyceride. The mean increase in fasting triglyceride was 71 mg/dL (54%) in the clozapine group and 39 mg/dL (35%) in the chlorpromazine group. In addition, clozapine treatment was associated with categorical increases in serum total cholesterol and fasting triglyceride, as illustrated in Table 5. The proportion of patients with categorical increases in total cholesterol or fasting triglyceride increased with the duration of exposure. The median duration of clozapine and chlorpromazine exposure was 45 days and 38 days, respectively. The clozapine dose range was 100 mg to 900 mg daily; the maximum chlorpromazine dose was 1800 mg daily.

Table 5: Mean Changes in Total Cholesterol and Triglyceride Concentration in Studies in Adult Subjects with Schizophrenia

<table>
<thead>
<tr>
<th>Treatment Arm</th>
<th>Baseline total cholesterol concentration (mg/dL)</th>
<th>Change from baseline mg/dL (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clozapine (N = 334)</td>
<td>184</td>
<td>+13 (7)</td>
</tr>
<tr>
<td>Chlorpromazine (N = 185)</td>
<td>182</td>
<td>+15 (8)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Treatment Arm</th>
<th>Baseline triglyceride concentration (mg/dL)</th>
<th>Change from baseline mg/dL (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clozapine (N = 6)</td>
<td>130</td>
<td>+71 (54)</td>
</tr>
<tr>
<td>Chlorpromazine (N = 7)</td>
<td>110</td>
<td>+39 (35)</td>
</tr>
</tbody>
</table>

5.11 Neuroleptic Malignant Syndrome

Antipsychotic drugs including clozapine can cause a potentially fatal symptomatic complex referred to as Neuroleptic Malignant Syndrome (NMS). Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status, and autonomic

Table 6: Categorical Changes in Lipid Concentrations in Studies in Adult Subjects with Schizophrenia

<table>
<thead>
<tr>
<th>Laboratory Parameter</th>
<th>Category Change (at least once) from baseline</th>
<th>Treatment Arm</th>
<th>N</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Cholesterol</td>
<td>Increase by ≥ 40 mg/dL</td>
<td>Clozapine</td>
<td>334</td>
<td>111 (33)</td>
</tr>
<tr>
<td></td>
<td>Normal (&lt; 200 mg/dL) to High (≥ 240 mg/dL)</td>
<td>Clozapine</td>
<td>222</td>
<td>18 (8)</td>
</tr>
<tr>
<td></td>
<td>Borderline (200 to 239 mg/dL) to High (≥ 240 mg/dL)</td>
<td>Clozapine</td>
<td>132</td>
<td>3 (2)</td>
</tr>
<tr>
<td></td>
<td>Increase by ≥ 50 mg/dL</td>
<td>Clozapine</td>
<td>69</td>
<td>3 (50)</td>
</tr>
<tr>
<td></td>
<td>Normal (&lt; 150 mg/dL) to High (≥ 200 mg/dL)</td>
<td>Clozapine</td>
<td>4</td>
<td>0 (0)</td>
</tr>
<tr>
<td></td>
<td>Borderline ( ≥ 150 mg/dL and &lt; 200 mg/dL) to High (≥ 200 mg/dL)</td>
<td>Clozapine</td>
<td>6</td>
<td>2 (33)</td>
</tr>
</tbody>
</table>

| Triglycerides (fasting) | Increase by ≥ 150 mg/dL | Clozapine | 1 | 1 (100) |
|                        |                        | Chlorpromazine | 1 | 0 (0) |

Weight Gain

Weight gain has occurred with the use of antipsychotics, including clozapine. Monitor weight during treatment with clozapine. Table 7 summarizes the data on weight gain by the duration of exposure pooled from 11 studies with clozapine and active comparators. The median duration of exposure was 609, 728, and 42 days, in the clozapine, olanzapine, and chlorpromazine group, respectively.

Table 7: Mean Change in Body Weight (kg) by Duration of Exposure from Studies in Adult Subjects with Schizophrenia

<table>
<thead>
<tr>
<th>Metabolic parameter</th>
<th>Exposure duration</th>
<th>Clozapine (N = 669)</th>
<th>Olanzapine (N = 442)</th>
<th>Chlorpromazine (N = 155)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>Mean</td>
<td>n</td>
<td>Mean</td>
</tr>
<tr>
<td>2 weeks</td>
<td>6</td>
<td>+0.9</td>
<td>3</td>
<td>+0.7</td>
</tr>
<tr>
<td></td>
<td>4 weeks (Day 21 to 35)</td>
<td>23</td>
<td>+0.7</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>8 weeks (Day 49 to 63)</td>
<td>12</td>
<td>+1.9</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>12 weeks (Day 70 to 98)</td>
<td>17</td>
<td>+2.8</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>24 weeks (Day 154 to 182)</td>
<td>42</td>
<td>-0.6</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>48 weeks (Day 322 to 350)</td>
<td>3</td>
<td>+3.7</td>
<td>3</td>
</tr>
</tbody>
</table>

Table 8 summarizes pooled data from 11 studies in adult subjects with schizophrenia demonstrating weight gain ≥ 7% of body weight relative to baseline. The median duration of exposure was 609, 728, and 42 days, in the clozapine, olanzapine, and chlorpromazine group, respectively.

Table 8: Proportion of Adult Subjects in Schizophrenia Studies with Weight Gain ≥ 7% Relative to Baseline Body Weight

<table>
<thead>
<tr>
<th>Weight change</th>
<th>Clozapine</th>
<th>Olanzapine</th>
<th>Chlorpromazine</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>669</td>
<td>442</td>
<td>155</td>
</tr>
<tr>
<td>≥ 7% (inclusive)</td>
<td>236 (35%)</td>
<td>203 (46%)</td>
<td>13 (8%)</td>
</tr>
</tbody>
</table>
instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias). Associated findings can include elevated creatine phosphokinase (CPK), myoglobinuria, rhabdomyolysis, and acute renal failure. The diagnostic evaluation of patients with this syndrome is complicated. It is important to consider the presence of other serious medical conditions (e.g., severe neutropenia, infection, heat stroke, primary CNS pathology, central anticholinergic toxicity, extrapyramidal symptoms, and drug fever).

The management of NMS should include (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, (2) intensive symptomatic treatment and medical monitoring, and (3) treatment of comorbid medical conditions. There is no general agreement about specific pharmacological treatments for NMS.

If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. NMS can recur. Monitor closely if restarting treatment with antipsychotics.

5.13 Fever
During clozapine therapy, patients have experienced transient, clozapine-related fever. The peak incidence is within the first 3 weeks of treatment. While this fever is generally benign and self-limited, it may necessitate discontinuing treatment. The fever increases with an increase in dose in WBC count. Carefully evaluate patients with fever to rule out severe neutropenia or infection. Consider the possibility of NMS [see Warnings and Precautions (5.11)].

5.14 Pulmonary Embolism
Pulmonary embolism and deep-vein thrombosis have occurred in patients treated with clozapine tablets. Consider the possibility of pulmonary embolism in patients who present with deep-vein thrombosis, acute dyspnea, chest pain, or with other respiratory signs and symptoms. Whether pulmonary embolus and deep-vein thrombosis can be attributed to clozapine or some characteristic(s) of patients is not clear.

5.15 Anticholinergic Toxicity
Clozapine has potent anticholinergic effects. Treatment with clozapine can result in CNS and peripheral anticholinergic toxicity. Use with caution in the presence of narrow-angle glaucoma, concomitant anticholinergic medications, prostatic hypertrophy, or other conditions in which anticholinergic effects can lead to significant adverse reactions. Treatment with clozapine can result in gastrointestinal adverse reactions, including constipation, intestinal obstruction, fecal impaction, and paralytic ileus. Such reactions can be fatal. Constipation should be initially treated by ensuring adequate hydration and use of ancillary therapy such as bulk laxatives. Consultation with a gastroenterologist is advisable in more serious cases.

5.16 Interference with Cognitive and Motor Performance
Clozapine can cause sedation and impairment of cognitive and motor performance. Caution patients about operating hazardous machinery, including automobiles, until they are reasonably certain that clozapine does not affect them adversely. These reactions may be dose-related. Consider reducing the dose if they occur.

5.17 Tardive Dyskinesia
Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs, including clozapine. The syndrome consists of potentially irreversible, involuntary, dyskinetic movements. The risk of TD and the likelihood that it will become irreversible are believed to increase with greater durations of treatment and higher total cumulative doses. However, the syndrome can develop after relatively brief treatment periods at low doses. Prescribe clozapine in a manner that is most likely to minimize the risk of developing TD. Use the lowest effective dose and the shortest duration of treatment for the indication involved. Periodically assess the need for continued treatment. Consider discontinuing treatment if TD occurs. However, some patients may require treatment with clozapine despite the presence of the syndrome. There is no known treatment for TD. However, the syndrome may remit partially or completely if treatment is discontinued. Antipsychotic treatment, itself, may suppress (or partially suppress) the signs and symptoms, and it has the potential to mask the underlying process. The effect of symptom suppression on the long-term course of TD is unknown.

5.18 Cerebrovascular Adverse Reactions
In controlled trials, elderly patients with dementia-related psychosis treated with some atypical antipsychotics had an increased risk (compared to placebo) of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack), including fatalities. The mechanism for this increased risk is not known. An increased risk cannot be excluded for clozapine or other antipsychotics or other patient populations. Clozapine should be used with caution in patients with risk factors for cerebrovascular adverse reactions.

5.19 Recurrence of Psychosis and Cholinergic Rebound after Abrupt Discontinuation of Clozapine
If abrupt discontinuation of clozapine is necessary (because of severe neutropenia or another medical condition, for example) [see Dosage and Administration (2.4), Warnings and Precautions (5.1)], monitor carefully for the recurrence of psychotic symptoms and adverse reactions related to cholinergic rebound, such as profuse sweating, headache, nausea, vomiting and diarrhea.

6 ADVERSE REACTIONS
The following adverse reactions are discussed in more detail in other sections of the labeling:

- Severe Neutropenia [see Warnings and Precautions (5.1)].
- Orthostatic Hypotension, Bradycardia, and Syncope [see Warnings and Precautions (5.3)].
- Falls [see Warnings and Precautions (5.4)].
- Seizures [see Warnings and Precautions (5.5)].
- Myocarditis, Cardiomyopathy and Mitral Valve Incompetence [see Warnings and Precautions (5.6)].
- Increased Mortality in Elderly Patients with Dementia-Related Psychosis [see Warnings and Precautions (5.7)].
- Esophagitis [see Warnings and Precautions (5.8)].
- QT Interval Prolongation [see Warnings and Precautions (5.9)].
- Metabolic Changes (Hyperglycemia and Diabetes Mellitus, Dyslipidemia, and Weight Gain) [see Warnings and Precautions (5.10)].
- Neuroleptic Malignant Syndrome [see Warnings and Precautions (5.11)].
- Hepatotoxicity [see Warnings and Precautions (5.12)].
- Fever [see Warnings and Precautions (5.13)].
- Pulmonary Embolism [see Warnings and Precautions (5.14)].
- Anticholinergic Toxicity [see Warnings and Precautions (5.15)].
- Interference with Cognitive and Motor Performance [see Warnings and Precautions (5.16)].
- Tardive Dyskinesia [see Warnings and Precautions (5.17)].
- Cerebrovascular Adverse Reactions [see Warnings and Precautions (5.18)].
- Recurrence of Psychosis and Cholinergic Rebound after Abrupt Discontinuation [see Warnings and Precautions (5.19)].

6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The most commonly reported adverse reactions (≥5%) across clozapine clinical trials were: CNS reactions, including sedation, dizziness/vertigo, headache, and tremor; cardiovascular reactions, including tachycardia, hypotension, and syncope; autonomic nervous system reactions, including hypersalivation, sweating, dry mouth, and visual disturbances; gastrointestinal reactions, including constipation and nausea; and fever. Table 9 summarizes the most commonly reported adverse reactions (≥5%) in clozapine-treated patients (compared to chlorpromazine-treated patients) in the pivotal, 6 week, controlled trial in treatment-resistant schizophrenia.

Table 9: Common Adverse Reactions (≥ 5%) in the 6 Week, Randomized, Chlorpromazine-controlled Trial in Treatment-Resistant Schizophrenia

<table>
<thead>
<tr>
<th>Adverse Reaction*</th>
<th>Chlorpromazine (N = 126) (%)</th>
<th>Clozapine (N = 142) (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sedation</td>
<td>21</td>
<td>13</td>
</tr>
<tr>
<td>Tachycardia</td>
<td>17</td>
<td>11</td>
</tr>
<tr>
<td>Constipation</td>
<td>16</td>
<td>12</td>
</tr>
<tr>
<td>Dizziness</td>
<td>14</td>
<td>16</td>
</tr>
<tr>
<td>Hypotension</td>
<td>13</td>
<td>38</td>
</tr>
<tr>
<td>Fever (hyperthermia)</td>
<td>13</td>
<td>4</td>
</tr>
<tr>
<td>Hypersalivation</td>
<td>12</td>
<td>5</td>
</tr>
<tr>
<td>Hypertension</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Headache</td>
<td>10</td>
<td>12</td>
</tr>
<tr>
<td>Nausea/vomiting</td>
<td>5</td>
<td>20</td>
</tr>
</tbody>
</table>

Table 10 summarizes the adverse reactions reported in clozapine-treated patients at a frequency of 2% or greater across all clozapine studies (excluding the 2 year InterSePT™ Study). These rates are not adjusted for duration of exposure.

Table 10: Adverse Reactions (≥ 2%) Reported in Clozapine-treated Patients (N = 842) Across All Clozapine Studies (excluding the 2 year InterSePT™ Study)

<table>
<thead>
<tr>
<th>Body System</th>
<th>Clozapine N = 842 Percentage of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central Nervous System</td>
<td></td>
</tr>
<tr>
<td>Drowsiness/Sedation</td>
<td>39</td>
</tr>
<tr>
<td>Dizziness/Vertigo</td>
<td>19</td>
</tr>
<tr>
<td>Headache</td>
<td>7</td>
</tr>
<tr>
<td>Tremor</td>
<td>6</td>
</tr>
<tr>
<td>Syncope</td>
<td>6</td>
</tr>
<tr>
<td>Disturbed Sleep/Nightmares</td>
<td>4</td>
</tr>
<tr>
<td>Restlessness</td>
<td>4</td>
</tr>
<tr>
<td>Hypokinesia/Akinesia</td>
<td>4</td>
</tr>
<tr>
<td>Agitation</td>
<td>4</td>
</tr>
<tr>
<td>Seizures (convulsions)</td>
<td>3%</td>
</tr>
<tr>
<td>Rigidity</td>
<td>3</td>
</tr>
</tbody>
</table>

continued
CLOZAPINE TABLETS

Adverse Reaction*  Clozapine  N = 479  Percentage of Patients

Central Nervous System continued
Akathisia  3
Confusion  3
Fatigue  2
Insomnia  2
Cardiovascular
Tachycardia  25%
Hypotension  9
Hypertension  4
Gastrointestinal
Constipation  14
Nausea  5
Abdominal discomfort/Heartburn  4
Nausea/Vomiting  3
Vomiting  3
Diarrhea  2
Urogenital
Urinary abnormalities  2
Autonomic Nervous System
Salivation  31
Sweating  17
Dry mouth  10
Visual disturbances  5
Skin
Rash  2
Hemic/Lymphatic
Leukopenia/Decreased WBC/Neutropenia  3
Miscellaneous
Fever  5
Weight Gain  4

* Rate based on population of approximately 1700 exposed during premarket clinical evaluation of clozapine.

Table 11 summarizes the most commonly reported adverse reactions (≥ 10% in the clozapine or olanzapine group) in the InterSePT™ Study. This was an adequate and well-controlled, two-year study evaluating the efficacy of clozapine relative to olanzapine in reducing the risk of suicidal behavior in patients with schizophrenia or schizoaffective disorder. The rates are not adjusted for duration of exposure.

Table 11: Incidence of Adverse Reactions in Patients Treated with Clozapine or Olanzapine in the InterSePT™ Study (≥ 10% in the clozapine or olanzapine group)

<table>
<thead>
<tr>
<th>Adverse Reactions</th>
<th>Clozapine N = 479</th>
<th>Olanzapine N = 477</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salivary hypersecretion</td>
<td>48</td>
<td>6</td>
</tr>
<tr>
<td>Somnolence</td>
<td>46</td>
<td>25</td>
</tr>
<tr>
<td>Weight increased</td>
<td>31</td>
<td>56</td>
</tr>
<tr>
<td>Dizziness (excluding vertigo)</td>
<td>27</td>
<td>12</td>
</tr>
<tr>
<td>Constipation</td>
<td>25</td>
<td>10</td>
</tr>
<tr>
<td>Insomnia</td>
<td>20</td>
<td>33</td>
</tr>
<tr>
<td>Nausea</td>
<td>17</td>
<td>10</td>
</tr>
<tr>
<td>Vomiting</td>
<td>17</td>
<td>9</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>14</td>
<td>8</td>
</tr>
</tbody>
</table>

Dystonia
Class effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.

6.2 Postmarketing Experience
The following adverse reactions have been identified during post-approval use of clozapine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Central Nervous System
Delirium, EEG abnormal, myoclonus, paresisia, possible cataplexy, status epilepticus, obsessive compulsive symptoms, and post-discontinuation cholinergic rebound adverse reactions.

Cardiovascular System
Atrial or ventricular fibrillation, ventricular tachycardia, palpitations, QT interval prolongation, Torsades de Pointes, mitral valve incompetence associated with clozapine-related cardiomyopathy, myocardial infarction, cardiac arrest, and periorbital edema.

Endocrine System
Pseudopheochromocytoma

Gastrointestinal System
Acute pancreatitis, dysphagia, salivary gland swelling, colitis.

Hepatobiliary System
Cholestasis, hepatitis, jaundice, hepatotoxicity, hepatic steatosis, hepatic necrosis, hepatic fibrosis, hepatic cirrhosis, liver injury (hepatic, cholestatic, and mixed), and liver failure.

Immune System Disorders
Angioedema, leukocytoclastic vasculitis.

Musculoskeletal System and Connective Tissue Disorders
Acute intestinal nephritis, nocturnal enuresis, priapism, renal failure, and retrograde ejaculation.

Skin and Subcutaneous Tissue Disorders
Hypersensitivity reactions: photosensitivity, vasculitis, erythema multiforme, skin pigmentation disorder, and Stevens-Johnson syndrome.

Vascular System
Aspiration, pleural effusion, pneumonia, lower respiratory tract infection, sleep apnea.

Hemic and Lymphatic System
Mild, moderate, or severe leukopenia, agranulocytosis, granulocytopenia, WBC decreased, deep-vein thrombosis, elevated hemoglobin/hematocrit, erythrocyte sedimentation rate (ESR) increased, sepsis, thrombocytosis, and thrombocytopenia.

Vision Disorders
Narrow-angle glaucoma.

Miscellaneous
Carcinoma

7 DRUG INTERACTIONS

7.1 Potential for Other Drugs to Affect Clozapine
Clozapine is a substrate for many cytochrome P450 isozymes, in particular CYP1A2, CYP3A4, and CYP2D6. Use caution when administering clozapine tablets concomitantly with drugs that are inducers or inhibitors of these enzymes.

CYP1A2 Inhibitors
Concomitant use of clozapine tablets and CYP1A2 inhibitors can increase plasma levels of clozapine, potentially resulting in adverse reactions. Reduce the clozapine tablets dose to one-third of the original dose when coadministering with CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, or tenofovir). The clozapine tablets dose should be increased to the original dose when coadministration of strong CYP1A2 inhibitors is discontinued [see Dosage and Administration (2.6), Clinical Pharmacology (12.3)]. Use caution when administering concomitant medications that prolong the QT interval.

CYP2D6 and CYP3A4 Inhibitors
Concomitant treatment with clozapine tablets and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sorbitol) can increase clozapine levels and lead to adverse reactions [see Clinical Pharmacology (12.3)]. Use caution when using such inhibitors. Consider reducing the clozapine tablets dose when using such inhibitors.

CYP2D6 and CYP3A4 Inducers
Concomitant treatment with drugs that induce CYP1A2 or CYP3A4 can decrease the plasma concentration of clozapine, resulting in decreased effectiveness of clozapine tablets. Tobacco smoke is a moderate inducer of CYP1A2. Strong CYP3A4 inducers include carbamazepine, phenytoin, St. John's wort, and rifampin. It may be necessary to decrease the clozapine tablets dose if used concomitantly with inducers of these enzymes. However, concomitant use of clozapine tablets and strong CYP3A4 inducers is not recommended [see Dosage and Administration (2.6)].

CYP2D6 and CYP3A4 Inhibitors
Concomitant treatment with drugs that inhibit CYP1A2 can decrease the plasma concentration of clozapine, resulting in increased effectiveness of clozapine tablets. Use caution when administering concomitant medications that may affect clozapine levels.

7.2 Potential for Clozapine to Affect Other Drugs
Concomitant use of clozapine tablets with other drugs metabolized by CYP2D6 can increase levels of these CYP2D6 substrates. Use caution when coadministering clozapine tablets with other drugs that are metabolized by CYP2D6. It may be necessary to use lower doses of such drugs than usually prescribed. Such drugs include specific antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide).

7.3 Drugs that Cause QT Interval Prolongation
Use caution when administering concomitant medications that prolong the QT interval or inhibit the metabolism of clozapine. Drugs that cause QT prolongation include: specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, thioridazine, mesoridazine, droperidol, and pimozide), specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin), Class I antiarrhythmics (e.g., quinidine, procainamide) or Class III antiarrhythmics (e.g., amiodarone, sotalol), and others (e.g., pentamidine, levemethadyl acetate, methadone, halofantrine, melphalan, dexamethasone, propofol, or tacrolimus) [see Warnings and Precautions (5.9)].
8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category B

Risk Summary

There are no adequate or well-controlled studies of clozapine in pregnant women. Reproduction studies have been performed in rats and rabbits at doses up to 0.4 and 0.9 times, respectively, the maximum recommended human dose (MRHD) of 900 mg/day on a mg/m² body surface area basis. The studies revealed no evidence of impaired fertility or harm to the fetus due to clozapine. Because animal reproduction studies are not always predictive of human response, clozapine tablets should be used during pregnancy only if clearly needed.

Clinical Considerations

Consider the risk of exacerbation of psychosis when discontinuing or changing treatment with antipsychotic medications during pregnancy and postpartum. Consider early screening for gestational diabetes for patients treated with antipsychotic medications [see Warnings and Precautions (5.10)]. Neonates exposed to antipsychotics during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. Monitor neonates for symptoms of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding difficulties. The severity of complications can vary from self-limited symptoms to some neonates requiring intensive care unit support and prolonged hospitalization.

Animal Data

In embryofetal developmental studies, clozapine had no effects on maternal parameters, litter sizes, or fetal parameters when administered orally to pregnant rats and rabbits during the period of organogenesis at doses up to 0.4 and 0.9 times, respectively, the MRHD of 900 mg/day on a mg/m² body surface area basis. In peri/postnatal developmental studies, pregnant female rats were administered clozapine over the last third of pregnancy and until day 21 postpartum. Observations were made on fetuses at birth and during the postnatal period; the offspring were allowed to reach sexual maturity and mated. Clozapine caused a decrease in maternal body weight but had no effects on litter size or body weights of either F1 or F2 generations at doses up to 0.4 times the MRHD of 900 mg/day on a mg/m² body surface area basis.

8.3 Nursing Mothers

Clozapine is present in human milk. Because of the potential for serious adverse reactions in nursing infants from clozapine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

8.4 Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

8.5 Geriatric Use

There have not been sufficient numbers of geriatric patients in clinical studies utilizing clozapine to determine whether those over 65 years of age differ from younger subjects in their response to clozapine.

Orthostatic hypotension and tachycardia can occur with clozapine treatment [see Boxed Warning and Warnings and Precautions (5.3)]. Elderly patients, particularly those with compromised cardiovascular functioning, may be more susceptible to these effects. Elderly patients may be particularly susceptible to the anticholinergic effects of clozapine, such as urinary retention and constipation [see Warnings and Precautions (5.15)].

8.6 Patients with Renal or Hepatic Impairment

Dose reduction may be necessary in patients with significant impairment of renal or hepatic function. Clozapine concentrations may be increased in these patients, because clozapine is almost completely metabolized and then excreted [see Dosage and Administration (2.7), Clinical Pharmacology (12.3)].

8.7 CYP2D6 Poor Metabolizers

Dose reduction may be necessary in patients who are CYP2D6 poor metabolizers. Clozapine concentrations may be increased in these patients, because clozapine is almost completely metabolized and then excreted [see Dosage and Administration (2.7), Clinical Pharmacology (12.3)].

8.8 Hospice Patients

For hospice patients (i.e., terminally ill patients with an estimated life expectancy of six months or less), the prescriber may reduce the ANC monitoring frequency to once every 6 months, after a discussion with the patient and his/her caregiver. Individual treatment decisions should weigh the importance of monitoring ANC in the context of the need to control psychiatric symptoms and the patient’s terminal illness.

10 OVERDOSAGE

10.1 Overdosage Experience

The most commonly reported signs and symptoms associated with clozapine overdose are: sedation, delirium, coma, tachycardia, hypotension, respiratory depression or failure, and hypersalivation. There are reports of aspiration pneumonia, cardiac arrhythmias, and seizure. Fatal overdoses have been reported with clozapine, generally at doses above 2500 mg. There have also been reports of patients recovering from overdoses well in excess of 4 g.

10.2 Management of Overdosage

For the most up-to-date information on the management of clozapine overdose, contact a certified Regional Poison Control Center (1-800-222-1222). Telephone numbers of certified Regional Poison Control Centers are listed in the Physicians’ Desk Reference®. Establish and maintain an airway; ensure adequate oxygenation and ventilation. Monitor cardiac status and vital signs. Use general symptomatic and supportive measures. There are no specific antidotes for clozapine.

In managing overdosage, consider the possibility of multiple-drug involvement.

11 DESCRIPTION

Clozapine tablets USP, an atypical antipsychotic drug, is a tricyclic dibenzodiazepine derivative. The chemical name of clozapine, USP is 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo [b,e] [1,4] diazepine and it has the following structural formula:

CLOZAPINE TABLETS

CLOZAPINE TABLETS

CLOZAPINE TABLETS
13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis
No carcinogenic potential was demonstrated in long-term studies in mice and rats. Clozapine had no effect on any parameters of fertility, pregnancy, fetal weight or postnatal development when administered orally to male rats 70 days before mating and females 14 days before mating, and to rats at doses up to 1000 mg/kg/day and 300 mg/kg/day, respectively, for 2 generations. There was no evidence of an increased incidence of neoplasms in either sex in rats or mice treated with clozapine up to doses of 50 to 100 times the maximum human dose (based on mg/m² body surface area). A single generation study in hamsters revealed an increased incidence of hamartomas at 3 times the maximum human dose. No carcinogenic potential was demonstrated in long-term studies in mice and rats. 

Mutagenesis
Clozapine was not genotoxic when tested in the following gene mutation and chromosomal aberration tests: the bacterial Ames test, the in vitro mammalian V79 chromosomal aberration test, and the in vitro unscheduled DNA synthesis test in rat hepatocytes or the in vivo micronucleus assay in mice.

Impairment of Fertility
Clozapine has not been studied for its effect on fertility in humans. In a study of schizophrenic patients (n = 14) who received clozapine under steady-state conditions, coadministration of fluvoxamine for 14 days, mean trough concentrations of clozapine and its metabolites, N-desmethylclozapine and clozapine N-oxide, were elevated about three-fold compared to baseline steady-state concentrations. No carcinogenic potential was demonstrated in long-term studies in mice and rats. Carcinogenesis

CYP2D6 Poor Metabolizers
A subset (3% to 10%) of the population has reduced activity of CYP2D6 (CYP2D6 poor metabolizers). These individuals may develop higher than expected plasma concentrations of clozapine when given usual doses.

14 CLINICAL STUDIES

14.1 Treatment-Resistant Schizophrenia
The efficacy of clozapine in treatment-resistant schizophrenic schizophrenia was established in a multicenter, randomized, double-blind, active-controlled (chlorpromazine) study in patients with a DSM-III diagnosis of schizophrenia who had inadequate responses to at least 3 different antipsychotics (from at least 2 different chemical classes) during the preceding 5 years. The antipsychotic trials must have been judged adequate; the antipsychotic dosages must have been equivalent to or greater than 1000 mg per day of chlorpromazine for a period of at least 6 weeks, each without significant reduction of symptoms. There must have been no period of good functioning within the preceding 5 years. Patients must have had a baseline score of at least 45 on the investigator-rated Brief Psychiatric Rating Scale (BPRS). On the 18-item BPRS, 1 indicates minimal symptoms, and 7 indicates severe symptoms; the maximum potential total BPRS score is 126. At baseline, the mean BPRS score was 61. In addition, patients must have had a score of at least 4 on at least two of the following four individual BPRS items: conceptual disorganization, suspiciousness, hallucinatory behavior, and unusual thought content. Patients must have had a Clinical Global Impressions–Severity Scale score of at least 4 (moderately ill).

In the prospective, lead-in phase of the trial, all patients (n = 305) initially received single-blind treatment with haloperidol (the mean dose was 61 mg per day) for 6 weeks. More than 80% of patients completed the 6 week trial. Patients with an inadequate response to haloperidol (n = 268) were randomized to double-blind treatment with clozapine (N = 126) or chlorpromazine (N = 142). The maximum daily clozapine dose was 900 mg; the mean daily dose was > 600 mg. The maximum daily chlorpromazine dose was 1800 mg; the mean daily dose was > 1200 mg.

The primary endpoint was treatment response, defined as a decrease in BPRS score of at least 20% and either (1) a CGI-S score of ≤ 3 (mildly ill), or (2) a BPRS score of ≤ 50 at the end of 6 weeks of treatment. Approximately 88% of patients from the clozapine and chlorpromazine groups completed the 6 week trial. At the end of 6 weeks, 30% of the clozapine group responded to treatment, and 4% of the chlorpromazine group responded to treatment. The difference was statistically significant (p < 0.001). The mean change in total BPRS score was -16 and -5 in the clozapine and chlorpromazine groups, respectively; the mean change in the 4 key BPRS item scores was -5 and -2 in the clozapine and chlorpromazine group, respectively, and the mean change in CGI-S score was -1.2 and -0.4, in the clozapine and chlorpromazine group, respectively. These changes in the clozapine group were statistically significantly greater than in the chlorpromazine group (p < 0.001 in each analysis).

14.2 The Current Suicidal Behavior in Schizophrenia or Schizoaffective Disorder

The effectiveness of clozapine in reducing the risk of recurrent suicidal behavior was assessed in the International Suicide Prevention Trial (InterSePTTM). This was a prospective, randomized, open-label, active-controlled, multicenter, international, parallel-group comparison of clozapine versus olanzapine (Zyprexa®) in 956 patients with schizophrenia or schizoaffective disorder (DSM-IV) who were judged to be at risk for recurrent suicidal behavior. Only about one-fourth of these patients (27%) were considered resistant to standard antipsychotic drug treatment. To enter the trial, patients must have met 1 of the following criteria:

- They had attempted suicide within the three years prior to their baseline evaluation.
- They had been hospitalized to prevent a suicide attempt within the three years prior to their baseline evaluation.
- They demonstrated moderate-to-severe suicidal ideation with a depressive component within one week prior to their baseline evaluation.
- They demonstrated moderate-to-severe suicidal ideation accompanied by command hallucinations to do self-harm within one week prior to their baseline evaluation.

Dosing regimens for each treatment group were determined by individual investigators and were individualized by patient. Dosing was flexible, with a dose range of 200 to 900 mg/day for clozapine and 5 to 20 mg/day for olanzapine. For the 956 patients who received clozapine or olanzapine in this study, there was extensive use of concomitant psychotropics: 84% with antipsychotics, 65% with anxiolytics, 53% with antidepressants, 28% with mood stabilizers. There was significantly greater use of concomitant psychiatric medications among the patients in the olanzapine group.

The primary efficacy measure was time to (1) a significant suicide attempt, including a completed suicide; (2) hospitalization due to imminent suicide risk, including increased level of surveillance for suicidality for patients already hospitalized; or (3) worsening of suicidality severity as demonstrated by “much worsening” or “very much worsening” from baseline in the Clinical Global Impression of Severity of Suicidality as assessed by the Blinded Psychiatrist (CGI-SS-BP) scale. A determination of whether or not a reported event met criterion 1 or 2 above was made by the Suicide Monitoring Board (SMB), a group of experts blinded to patient data. A total of 980 patients were randomized to the study and 956 received study medication. Sixty-two percent of the patients were diagnosed with schizophrenia, and the remainder (38%) were diagnosed with schizoaffective disorder. Only about one-fourth of the total patient population (27%) was identified as “treatment-resistant” at baseline. There were more males than females in the study (61% of all patients were male). The mean age of patients entering the study was 37 years of age (range 18 to 69). Most patients were Caucasian (71%), 15% were Black, 1% were Asian, and 13% were classified as being of “other” races.

Patients treated with clozapine had a statistically significant longer delay in the time to recurrent suicidal behavior in comparison with olanzapine. This result should be interpreted only as evidence of the effectiveness of clozapine in delaying time to recurrent suicidal behavior and not a demonstration of the superior efficacy of clozapine over olanzapine.

The probability of experiencing (1) a significant suicide attempt, including a completed suicide, or (2) hospitalization because of imminent suicide risk, including increased level of surveillance for suicidality for patients already hospitalized, was lower for clozapine patients than for olanzapine patients at Week 104: clozapine 24% versus olanzapine 32%; 95% CI of the difference: 2%, 14% (Figure 1).

Figure 1: Cumulative Probability of a Significant Suicide Attempt or Hospitalization to Prevent Suicide in Patients with Schizophrenia or Schizoaffective Disorder at High Risk of Suicidality

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied
Clozapine Tablets USP are available as pale yellow, round tablets, debossed “Ivax clozapine” and “4359” on one side and “25” and a bisect on the other side, containing 5 mg clozapine, USP.

NDC 0093-4359-05 25 mg packaged in bottles of 100 tablets
NDC 0093-4359-93 25 mg packaged in unit-dose boxes of 100 tablets

Clozapine Tablets USP are available as pale yellow, round, flat-faced, beveled-edge tablets, debossed “Ivax clozapine” and “4404” on one side and “50” and a bisect on the other side, containing 50 mg clozapine, USP.

NDC 0093-4404-01 50 mg packaged in bottles of 100 tablets
NDC 0093-4404-05 50 mg packaged in bottles of 500 tablets
NDC 0093-4404-93 50 mg packaged in unit-dose boxes of 100 tablets

16.2 Storage and Handling

Store at controlled room temperature 20°C to 25°C (68°F to 77°F).
CLOZAPINE TABLETS

Clozapine Tablets USP are available as pale yellow, round, flat-faced, beveled-edge tablets, debossed “Ivax hourglass logo” and “7772” on one side and “100” and a bisect on the other side, containing 100 mg clozapine, USP.

NDC 0093-7772-01 100 mg packaged in bottles of 100 tablets
NDC 0093-7772-05 100 mg packaged in bottles of 500 tablets
NDC 0093-7772-93 100 mg packaged in unit-dose boxes of 100 tablets

Clozapine Tablets USP are available as pale yellow, oval-shaped, biconvex tablets, debossed “Ivax hourglass logo” and “4405” on one side and “200” and a deep bisect on the other side, containing 200 mg clozapine, USP.

NDC 0093-4405-01 200 mg packaged in bottles of 100 tablets
NDC 0093-4405-05 200 mg packaged in bottles of 500 tablets
NDC 0093-4405-93 200 mg packaged in unit-dose boxes of 100 tablets

16.2 Storage and Handling
Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in a tight container as defined in the USP, with a child-resistant closure (as required).

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

17 PATIENT COUNSELING INFORMATION
Discuss the following issues with patients and caregivers:
• **Severe Neutropenia:**
  - INSTRUCT patients (and caregivers) beginning treatment with clozapine about the risk of developing severe neutropenia and infection.
  - INSTRUCT patients to immediately report to their physician any symptom or sign of infection (e.g., flu-like illness; fever; lethargy; general weakness or malaise; mucus membrane ulceration; skin, pharyngeal, vaginal, urinary, or pulmonary infection; or extreme weakness or lethargy) occurring at any time during clozapine therapy, to aid in evaluation for neutropenia and to institute prompt and appropriate management [see Warnings and Precautions (5.1), (5.11), and (5.13)].
  - INFORM patients and caregivers clozapine is available only through a restricted program called the Clozapine REMS Program designed to ensure the required blood monitoring, in order to reduce the risk of developing severe neutropenia. Advise patients and caregivers of the importance of having blood tested as follows:
    • Weekly blood tests are required for the first 6 months.
    • An ANC is required every 2 weeks for the next 6 months if an acceptable ANC is maintained during the first 6 months of continuous therapy.
    • An ANC is required once every 4 weeks thereafter if an acceptable ANC is maintained during the second 6 months of continuous therapy.
  - Clozapine is available only from certified pharmacies participating in the program. Provide patients (and caregivers) with website information and the telephone number on how to obtain the product (www.clozapinerems.com or 1-844-267-6878) [see Warnings and Precautions (5.2)].
• **Orthostatic Hypotension, Bradycardia, and Syncope:** INFORM patients and caregivers about the risk of orthostatic hypotension and syncope, especially during the period of initial dose titration. INSTRUCT them to strictly follow the clinician’s instructions for dosage and administration. ADVISE patients to consult their clinician immediately if they feel faint, lose consciousness or have signs or symptoms suggestive of bradycardia or arrhythmia [see Dosage and Administration (2.2) and Warnings and Precautions (5.3)].
• **Seizures:** INFORM patients and caregivers about the significant risk of seizure during clozapine treatment. Caution them about driving and any other potentially hazardous activity while taking clozapine [see Warnings and Precautions (5.5)].
• **QT Interval Prolongation:** ADVISE patients to consult their clinician immediately if they feel faint, lose consciousness or have signs or symptoms suggestive of arrhythmia. INSTRUCT patients to not take clozapine with other drugs that cause QT interval prolongation. INSTRUCT patients to inform their physicians that they are taking clozapine before any new drug [see Warnings and Precautions (5.9) and Drug Interactions (7.1)].
• **Metabolic Changes (hyperglycemia and diabetes mellitus, dyslipidemia, weight gain):** Educate patients and caregivers about the risk of metabolic changes and the need for specific monitoring. The risks include hyperglycemia and diabetes mellitus, dyslipidemia, weight gain, and cardiovascular reactions. Educate patients and caregivers about the symptoms of hyperglycemia (high blood sugar) and diabetes mellitus (e.g., polydipsia, polyuria, polyphagia, and weakness). Monitor all patients for these symptoms. Patients who are diagnosed with diabetes or have risk factors for diabetes (obesity, family history of diabetes) should have their fasting blood glucose monitored before beginning treatment and periodically during treatment. Patients who develop symptoms of hyperglycemia should have assessments of fasting glucose. Clinical monitoring of weight is recommended [see Warnings and Precautions (5.10)].
• **Interference with Cognitive and Motor Performance:** Because clozapine may have the potential to impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that clozapine therapy does not affect them adversely [see Warnings and Precautions (5.16)].
• **Missed Doses and Re-initiating Treatment:** Inform patients and caregivers that if the patient misses taking clozapine for more than 2 days, they should not restart their medication at the same dosage but should contact their physician for dosing instructions [see Dosage and Administration (2.5) and Warnings and Precautions (5.1, 5.3)].
WARNING: SEVERE NEUTROPENIA; ORTHOSTATIC HYPOTENSION, BRADYCARDIA, AND SYNCOPÉ; SEIZURE; MYOCARDITIS AND CARDIOMYOPATHY; INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

See full prescribing information for complete boxed warning.

- Severe Neutropenia: Clozapine can cause severe neutropenia, which can lead to serious and fatal infections. Patients initiating and continuing treatment with Clozapine ODT must have a baseline blood absolute neutrophil count (ANC) measured before treatment initiation and regular ANC monitoring during treatment (2.1, 5.1).

- Clozapine ODT is available only through a restricted program called the Clozapine REMS (5.2).

- Orthostatic Hypotension, Bradycardia, and Syncope: Risk is dose-related. Starting dose is 12.5 mg. Titrate gradually and use divided dosages (2.2, 2.6, 5.3).

- Seizure: Risk is dose-related. Titrate gradually and use divided doses. Use with caution in patients with history of seizure or risk factors for seizure (2.2, 5.5).

- Myocarditis and Cardiomyopathy: Can be fatal. Discontinue and obtain cardiac evaluation if findings suggest these cardiac reactions (5.6).

- Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Clozapine ODT is not approved for this condition (5.7).

RECENT MAJOR CHANGES

- Warnings and Precautions, Falls (5.4), Hepatotoxicity (5.12) 2/2017

INDICATIONS AND USAGE

Clozapine ODT is an atypical antipsychotic indicated for:

- Reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder.

- Treatment-resistant schizophrenia. Efficacy was established in an active-controlled study (1.2, 14.2).

- With dementia-related psychosis

CONTRAINDICATIONS

- Known serious hypersensitivity to clozapine or any other component of Clozapine ODT (4.1).

DOSE AND ADMINISTRATION

- Starting Dose: 12.5 mg once daily or twice daily (2.3).

- Use cautious titration and divided dosage schedule (2.3, 5.3).

- Titration: increase the total daily dosage in increments of 25 mg to 50 mg per day, if well-tolerated (2.3).

- Target dose: 300 mg to 450 mg per day, in divided doses, by the end of 2 weeks (2.3).

- Subsequent increases: increase in increments of 100 mg or less, once or twice weekly (2.3).

- Maximum daily dose: 900 mg (2.3).

- Tablets rapidly disintegrate after placement in the mouth and may be chewed if desired. No water is needed. Can be administered with or without food (2.3).

DOSE FORMS AND STRENGTHS

Orally disintegrating tablets: 12.5 mg, 25 mg, 100 mg, 150 mg and 200 mg (3).

CONTRAINDICATIONS

- Known serious hypersensitivity to clozapine or any other component of Clozapine ODT (4.1).

DRUG INTERACTIONS

- Concomitant use of Strong CYP1A2 Inhibitors: Reduce Clozapine ODT dose to one third when coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, enoxacin) (2.7, 7.1).

- Concomitant use of Strong CYP3A4 Inducers: Reduce Clozapine ODT dose when CYP3A4 inducers (e.g., barbiturates, phenytoin, rifampin) are used (2.7, 7.1).

- Dosage reductions of up to one third when coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, enoxacin) or strong CYP3A4 inducers (e.g., barbiturates, phenytoin, rifampin) (2.7, 7.1).

- Dosage Re-Initiation of Treatment: In exceptional cases, re-initiation of treatment may be attempted (2.7, 7.1).

- Dosage Adjustments with Concomitant use of CYP1A2, CYP2D6, CYP3A4 Inhibitors or CYP1A2, CYP3A4 Inducers

- Strong CYP1A2 Inhibitors: Reduce Clozapine ODT dose to one third when coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, enoxacin) (2.7, 7.1).

- Strong CYP3A4 Inducers: Reduce Clozapine ODT dose when CYP3A4 inducers (e.g., barbiturates, phenytoin, rifampin) are used (2.7, 7.1).

- Dosage Adjustments with Concomitant use of CYP1A2, CYP2D6, CYP3A4 Inhibitors or CYP1A2, CYP3A4 Inducers

- Inhibitors or CYP1A2, CYP2D6, CYP3A4 Inducers

- CYP1A2 Inhibitors: Reduce Clozapine ODT dose to one third when coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, enoxacin) (2.7, 7.1).

- CYP3A4 Inducers: Reduce Clozapine ODT dose when CYP3A4 inducers (e.g., barbiturates, phenytoin, rifampin) are used (2.7, 7.1).

ADVERSE REACTIONS

Most common adverse reactions (≥25%) were: CNS reactions (sedation, dizziness/ vertigo, headache, and tremor); cardiovascular reactions (tachycardia, hypotension, and syncope); autonomic nervous system reactions (hypersalivation, sweating, dry mouth, and visual disturbances); gastrointestinal reactions (constipation andnausea); and fever (6.1).

To report SUSPECTED ADVERSE REACTIONS, contact Jazz Pharmaceuticals, Inc., at 1-800-520-5568 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

USE IN SPECIFIC POPULATIONS

- Nursing Mothers: Discontinue drug or discontinue nursing, taking into consideration importance of drug to mother (8.3).

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 02/2017

FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: SEVERE NEUTROPENIA; ORTHOSTATIC HYPOTENSION, BRADYCARDIA, AND SYNCOPÉ; SEIZURE; MYOCARDITIS AND CARDIOMYOPATHY; INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

1 INDICATIONS AND USAGE

1.1 Treatment-Resistant Schizophrenia

1.2 Reduction in the Risk of Recurrent Suicidal Behavior in Schizophrenia or Schizoaffective Disorder

2 DOSAGE AND ADMINISTRATION

2.1 Required Laboratory Testing Prior to Initiation and During Therapy

2.2 Important Administration Instructions

2.3 Dosing Information

2.4 Maintenance Treatment

2.5 Discontinuation of Treatment

2.6 Re-Initiation of Treatment

2.7 Dosage Adjustments with Concomitant use of CYP1A2, CYP2D6, CYP3A4 Inhibitors or CYP1A2, CYP3A4 Inducers

2.8 Renal or Hepatic Impairment or CYP2D6 Poor Metabolizers

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

4.1 Hypersensitivity

5 WARNINGS AND PRECAUTIONS

5.1 Severe Neutropenia

5.2 Clozapine REMS Program

5.3 Orthostatic Hypotension, Bradycardia, and Syncope

5.4 Falls

5.5 Seizures

5.6 Myocarditis and Cardiomyopathy

5.7 Increased Mortality in Elderly Patients with Dementia-Related Psychosis

5.8 Eosinophilia

5.9 QT Interval Prolongation

5.10 Metabolic Changes

5.11 Neuroleptic Malignant Syndrome

5.12 Hepatotoxicity

5.13 Fever

5.14 Pulmonary Embolism

5.15 Anticholinergic Toxicity

5.16 Interference with Cognitive and Motor Performance

5.17 Tardive Dyskinesia

5.18 Patients with Phenylketonuria

5.19 Cerebrovascular Adverse Reactions

5.20 Recurrence of Psychosis and Cholinergic Rebound after Abrupt Discontinuation of Clozapine ODT

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

6.2 Postmarketing Experience

7 DRUG INTERACTIONS

7.1 Potential for Other Drugs to Affect Clozapine ODT

7.2 Potential for Clozapine ODT to Affect Other Drugs

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Nursing Mothers

8.3 Pediatric Use

8.4 Geriatric Use

8.5 Renal or Hepatic Impairment

8.6 Patients with Renal or Hepatic Impairment

8.7 CYP2D6 Poor Metabolizers

8.8 Hospice Patients

- Eosinophilia: Assess for organ involvement (e.g., myocarditis, pancreatitis, hepatitis, colitis, nephritis). Discontinue if these occur (5.8).

- QT Interval Prolongation: Can be fatal. Consider additional risk factors for prolonged QT interval (disorders and drugs) (5.9).

- Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include:

  - Hyperglycemia and Diabetes Mellitus: Monitor for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Monitor glucose regularly in patients with diabetes or at risk for diabetes (5.10).

  - Dyslipidemia: Undesirable alterations in lipids have occurred in patients treated with atypical antipsychotics (5.10).

  - Weight Gain: Significant weight gain has occurred. Monitor weight gain (5.10).

- Neuroleptic Malignant Syndrome (NMS): Immediately discontinue and monitor closely. Assess for co-morbid conditions (5.11).

- Hepatotoxicity: Can be fatal. Monitor for hepatotoxicity. Discontinue treatment if hepatitis or transaminase elevations combined with other symptoms occur (5.12).

- Fever: Evaluate for infection and neutropenia, NMS (5.13).

- Pulmonary Embolism (PE): Consider PE if respiratory distress, chest pain, or deep vein thrombosis occurs (5.14).

- Anticholinergic Toxicity: Use cautiously in presence of specific conditions (e.g., narrow angle glaucoma, use of anticholinergic drugs) (5.15).

- Interference with Cognitive and Motor Performance: Advise caution when operating machinery, including automobiles (5.16).
CLOZAPINE ODT (Orally Disintegrating Tablets) for oral use

10 OVERDOSAGE
10.1 Overdose Experience
10.2 Management of Overdosage

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

FULL PRESCRIBING INFORMATION

WARNING: SEVERE NEUTROPENIA; ORTHOSTATIC HYPOTENSION, BRADYCARDIA, AND SYNCPE; SEIZURE; MYOCARDITIS AND CARDIOMYOPATHY; INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSES

Severe Neutropenia
Clozapine treatment has caused severe neutropenia, defined as an absolute neutrophil count (ANC) less than 500/µL. Severe neutropenia can lead to serious infection and death. Prior to initiating treatment with Clozapine ODT a baseline ANC must be obtained. In patients who have received prior treatment with clozapine and have not been neutropenic, the ANC must be at least 1000/µL for patients with documented Benign Ethnic Neutropenia (BEN). During treatment, patients must have regular ANC monitoring. Advise patients to immediately report symptoms consistent with severe neutropenia or infection (e.g., fever, weakness, lethargy, or sore throat) [see Dosage and Administration (2.1) and Warnings and Precautions (5.1)].

Because of the risk of severe neutropenia, Clozapine ODT is available only through a restricted program under a Risk Evaluation Mitigation Strategy (REMS) called the Clozapine REMS Program [see Warnings and Precautions (5.2)].

Oral hypotension, Bradycardia, Syncope
Oral hypotension, bradycardia, syncope, and cardiac arrest have occurred with clozapine treatment. The risk is highest during the initial titration period, particularly with rapid dose escalation. These reactions can occur with the first dose, with doses as low as 12.5 mg per day. Initiate treatment at 12.5 mg once or twice daily; titrate slowly; and use divided dosages. Use clozapine cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration (2.3, 2.6) and Warnings and Precautions (5.3)].

Seizures
Seizures have occurred with clozapine treatment. The risk is dose-related. Initiate treatment at 12.5 mg, titrate gradually, and use divided dosing. Use caution when administering clozapine to patients with a history of seizures or other predisposing risk factors for seizure (CNS pathology, medications that lower the seizure threshold, alcohol abuse). Caution patients about engaging in any activity where sudden loss of consciousness could cause serious injury to themselves or others [see Dosage and Administration (2.3), Warnings and Precautions (5.5)].

Myocarditis and Cardiomyopathy
Fatal myocarditis and cardiomyopathy have occurred with clozapine treatment. Discontinue clozapine and obtain a cardiac evaluation upon suspicion of these reactions. Generally, patients with clozapine-related myocarditis or cardiomyopathy should not be rechallenged with clozapine. Consider the possibility of myocarditis or cardiomyopathy if chest pain, tachycardia, palpitations, dyspnea, fever, flu-like symptoms, hypotension, or ECG changes occur [see Warnings and Precautions (5.6)].

Increased Mortality in Elderly Patients with Dementia-Related Psychoses
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Clozapine ODT is not approved for use in patients with dementia-related psychosis [see Warnings and Precautions (5.7)].

1 INDICATIONS AND USAGE

1.1 Treatment-Resistant Schizophrenia
Clozapine ODT is indicated for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the risks of severe neutropenia and of seizure associated with its use, Clozapine ODT should be used only in patients who have failed to respond adequately to standard antipsychotic treatment [see Warnings and Precautions (5.1, 5.5)].

The effectiveness of clozapine in treatment-resistant schizophrenia was demonstrated over a two-year treatment period in the InterSePT™ trial [see Clinical Studies (14.1)].

1.2 Reduction in the Risk of Recurrent Suicidal Behavior in Schizophrenia or Schizoaffective Disorder
Clozapine ODT is indicated for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior, based on history and recent clinical state. Suicidal behavior refers to actions by a patient that put him/herself at risk for death. The effectiveness of clozapine in reducing the risk of recurrent suicidal behavior was demonstrated over a two-year treatment period in the InterSePT™ trial [see Clinical Studies (14.2)].

2 DOSAGE AND ADMINISTRATION

2.1 Required Laboratory Testing Prior to Initiation and During Therapy
Prior to initiating treatment with Clozapine ODT, a baseline ANC must be obtained. The baseline ANC must be at least 1500/µL for the general population, and at least 1000/µL for patients with documented Benign Ethnic Neutropenia (BEN). To continue treatment, the ANC must be monitored regularly [see Warnings and Precautions (5.1)].

2.2 Important Administration Instructions
Clozapine orally disintegrating tablets should be immediately placed in the mouth after removing the tablet from the blister pack or bottle. The tablet disintegrates rapidly after placement in the mouth. The tablets can be allowed to disintegrate, or they may be chewed. They may be swallowed with saliva. No water is necessary for administration.

The orally disintegrating tablets in a blister pack should be left in the unopened blister until the time of use. Just prior to use, peel the foil from the blister and gently remove the orally disintegrating tablet. Do not push the tablets through the foil, because this could damage the tablet.

2.3 Dosing Information
The starting dose is 12.5 mg once daily or twice daily. The total daily dose can be increased in increments of 25 mg to 50 mg per day, if well-tolerated, to achieve a target dose of 300 mg to 450 mg per day (administered in divided doses) by the end of the first week. Subsequently, the dose can be increased once weekly or twice weekly, in increments of up to 100 mg. The maximum dose is 900 mg per day. To minimize the risk of orthostatic hypotension, bradycardia, and syncope, it is necessary to use this low starting dose, gradual titration schedule, and divided dosages [see Warnings and Precautions (5.3)].

Clozapine ODT can be taken with or without food [see Pharmacokinetics (12.3)].

2.4 Maintenance Treatment
Generally, patients responding to Clozapine ODT should continue maintenance treatment on their effective dose beyond the acute episode.

2.5 Discontinuation of Treatment
Method of treatment discontinuation will vary depending on the patient’s last ANC:

• See Tables 2 or 3 for appropriate ANC monitoring based on the level of neutropenia if abrupt treatment discontinuation is necessary because of moderate to severe neutropenia.
• Reduce the dose gradually over a period of 1 to 2 weeks if termination of Clozapine ODT therapy is planned and there is no evidence of moderate to severe neutropenia.
• For abrupt clozapine discontinuation for a reason unrelated to neutropenia, continuation of the existing ANC monitoring is recommended for general population patients until their ANC is ≥1500/µL and for BEN patients until their ANC is ≥1000/µL or above their baseline.
• Additional ANC monitoring is required for any patient reporting onset of fever (temperature of 38.5°C or 101.3°F or greater) during the 2 weeks after discontinuation [see Warnings and Precautions (5.1)].
• Monitor all patients carefully for the recurrence of psychotic symptoms and symptoms related to cholinergic rebound such as profuse sweating, headache, nausea, vomiting, and diarrhea.

2.6 Re-initiation of Treatment
When restarting Clozapine ODT in patients who have discontinued Clozapine ODT (i.e., 2 days or more since the last dose), re-initiate with 12.5 mg once daily or twice daily. This is necessary to minimize the risk of hypotension, bradycardia, and syncope [see Warnings and Precautions (5.3)]. If that dose is well-tolerated, the dose may be increased to the previously therapeutic dose more quickly than recommended for initial treatment.

2.7 Dose Adjustments with Concomitant use of CYP1A2, CYP2D6, CYP3A4 Inducers or CYP1A2, CYP3A4 Inhibitors
Dose adjustments may be necessary in patients with concomitant use of: strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, or enoxacin); moderate or weak CYP1A2 inhibitors (e.g., oral contraceptives, or caffeine); CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, valproate, topiramate, or sertraline); CYP3A4 inducers (e.g., phenytoin, carbamazepine, St. John’s wort, and rifampin); or CYP1A2 inducers (e.g., tobacco smoking) (Table 1) [see Drug Interactions (7)].
CLOZAPINE ODT (Orally Disintegrating Tablets) for oral use

Co-medications Scenarios
Moderate or Weak CYP1A2 Inhibitors Monitor for adverse reactions. Consider reducing the Clozapine ODT dose if necessary.
CYP2D6 or CYP3A4 Inhibitors Monitor for lack of effectiveness. Consider increasing Clozapine ODT dose if necessary.
Strong CYP3A4 Inducers Concomitant use is not recommended. However, if the inducer is necessary, it may be necessary to increase the Clozapine ODT dose. Monitor for decreased effectiveness.
Moderate or Weak CYP1A2 or CYP3A4 Inducers Monitor for decreased effectiveness. Consider increasing the Clozapine ODT dose if necessary.

2.8 Renal or Hepatic Impairment or CYP2D6 Poor Metabolizers
It may be necessary to reduce the Clozapine ODT dose in patients with significant renal or hepatic impairment, or in CYP2D6 poor metabolizers [see Use in Specific Populations (8.6, 8.7)].

3 DOSAGE FORMS AND STRENGTHS
Clozapine ODT is available as 12.5 mg, 25 mg, 100 mg, 150 mg and 200 mg round, yellow, orally disintegrating tablets.

4 CONTRAINDICATIONS
4.1 Hypersensitivity
Clozapine ODT is contraindicated in patients with a history of serious hypersensitivity to clozapine (e.g., photosensitivity, vasculitis, erythema multiforme, or Stevens-Johnson Syndrome) or any other component of Clozapine ODT [see Adverse Reactions (6.2)].

5 WARNINGS AND PRECAUTIONS
5.1 Severe Neutropenia
Background
Clozapine ODT can cause neutropenia (a low absolute neutrophil count [ANC]), defined as a reduction below pre-treatment normal levels of blood neutrophils. The ANC is usually available as a component of the complete blood count (CBC), including differential, and is more relevant to drug-induced neutropenia than is the white blood cell (WBC) count. The ANC may also be calculated using the following formula: ANC equals Total WBC count multiplied by the total percentage of neutrophils obtained from the differential (neutrophil “segs” plus neutrophil “bands”). Other granulocytes (basophils and eosinophils) contribute minimally to neutropenia and their measurement is not necessary [see Adverse Reactions (6.2)]. Neutropenia may be mild, moderate, or severe (see Tables 2 and 3). To improve and standardize understanding, “severe neutropenia” replaces the previous terms severe leukopenia, severe granulocytopenia, or agranulocytosis.

Severe neutropenia, ANC less than (<) 500/μL, occurs in a small percentage of patients taking Clozapine ODT and is associated with an increase in the risk of serious and potentially fatal infections. Risk of neutropenia appears greatest during the first 18 weeks on treatment and then declines. The mechanism by which Clozapine ODT causes neutropenia is unknown and is not dose-dependent.

Two separate management algorithms are provided below, the first for patients in the general population, and the second for patients identified to have baseline neutropenia.

Clozapine ODT Treatment and Monitoring in the General Patient Population (see Table 2)

Obtain a CBC, including the ANC value, prior to initiating treatment with Clozapine ODT to ensure the presence of a normal baseline neutrophil count (equal to or greater than 1500/μL) and to permit later comparisons. Patients in the general population with an ANC equal to or greater than (>1500/μL) are considered within normal range (Table 2) and are eligible to initiate treatment. Weekly ANC monitoring is required for all patients during the first 6 months of treatment. If a patient's ANC remains equal to or greater than 1500/μL for the first 6 months of treatment, monitoring frequency may be reduced to every 2 months. If the next ANC remains equal to or greater than 1500/μL, for the second 6 months of continuous therapy, ANC monitoring frequency may be reduced to once every 4 weeks thereafter.

Table 2: Clozapine ODT Treatment Recommendations Based on Absolute Neutrophil Count (ANC) Monitoring for the General Patient Population

<table>
<thead>
<tr>
<th>ANC Level</th>
<th>Treatment Recommendations</th>
<th>ANC Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal range (&gt;1500/μL)</td>
<td>• Initiate treatment • If treatment interrupted: &lt; 30 days, continue monitoring as before • &gt;30 days, monitor as if new patient</td>
<td>• Weekly from initiation to 6 months • Every 2 weeks from 6 to 12 months • Monthly after 12 months</td>
</tr>
<tr>
<td>Mild Neutropenia (1000 to 1499/μL)*</td>
<td>• Discontinuation for reasons other than neutropenia</td>
<td>• See Section 2.4</td>
</tr>
<tr>
<td>* Confirm all initial reports of ANC less than 1500/μL with a repeat ANC measurement within 24 hours ** If clinically appropriate</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CLOZAPINE ODT (Orally Disintegrating Tablets) for oral use

Table 3: Patients with Benign Ethnic Neutropenia (BEN): Clozapine ODT Treatment Recommendations Based on Absolute Neutrophil Count (ANC) Monitoring

<table>
<thead>
<tr>
<th>ANC Level</th>
<th>Treatment Recommendations</th>
<th>ANC Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal BEN Range (Established ANC baseline &gt;1000/μL)</td>
<td>• Obtain at least two baseline ANC levels before initiating treatment • If treatment interrupted: &lt; 30 days, continue monitoring as before • &gt; 30 days, monitor as if new patient</td>
<td>• Weekly from initiation to 6 months • Every 2 weeks from 6 to 12 months • Monthly after 12 months</td>
</tr>
<tr>
<td>BEN Neutropenia (500 to 999/μL)</td>
<td>• Recommend hematology consultation • Continue treatment</td>
<td>• Three times weekly until ANC &gt;1000/μL or patient's known baseline • Once ANC &gt;1000/μL, check ANC weekly for 4 weeks, then return to patient's last &quot;Normal Range&quot; ANC monitoring interval **</td>
</tr>
<tr>
<td>BEN Severe Neutropenia (less than 500/μL)*</td>
<td>• Recommend hematology consultation • Interrupt treatment for suspected clozapine-induced neutropenia • Do not rechallenge unless prescriber determines benefits outweigh risks</td>
<td>• Daily until ANC &gt;500/μL, then • Three times weekly until ANC &gt;1500/μL • Once ANC &gt;1500/μL, check ANC weekly for 4 weeks, then return to patient's last &quot;Normal Range&quot; ANC monitoring interval **</td>
</tr>
</tbody>
</table>

* Confirm all initial reports of ANC less than 1500/μL with a repeat ANC measurement within 24 hours ** If clinically appropriate
5.6 Myocarditis and Cardiomyopathy

Myocarditis and cardiomyopathy have occurred with the use of clozapine. These reactions can be fatal. Discontinue Clozapine ODT and obtain a cardiac evaluation upon suspicion of myocarditis or cardiomyopathy. Generally, patients with a history of clozapine-associated myocarditis or cardiomyopathy should not be rechallenged with Clozapine ODT. However, the risk of Clozapine ODT treatment is judged to outweigh the potential risks of recurrent myocarditis or cardiomyopathy, the clinician may consider rechallenge with Clozapine ODT in consultation with a cardiologist, after a complete cardiac evaluation, and under close monitoring. Consider the possibility of mycarditis or cardiomyopathy in patients receiving Clozapine ODT who present with chest pain, dyspnea, persistent tachycardia at rest, palpitations, fever, flu-like symptoms, hypotension, other signs or symptoms of heart failure, or electrocardiographic findings (low voltages, ST-T abnormalities, arrhythmias, right axis deviation, and poor R wave progression). Myocarditis most frequently presents within the first two months of clozapine treatment. Symptoms of cardiomyopathy generally occur after several months of clozapine-associated myocarditis and usually after 8 weeks of treatment. However, myocarditis and cardiomyopathy can occur at any period during treatment with Clozapine ODT. It is common for nonspecific flu-like symptoms such as malaise, myalgia, pleuritic chest pain, and low-grade fevers to precede more overt signs of heart failure. Typical laboratory findings include elevated B-type natriuretic peptide (BNP) and highsensitivity C-reactive protein (CRP). Chest roentgenogram may demonstrate cardiac silhouette enlargement, and cardiac imaging (echocardiogram, radionuclide studies, or cardiac catheterization) may reveal evidence of left ventricular dysfunction.

5.7 Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Clozapine ODT may cause somnolence, postural hypotension, and motor and sensory instability, which may lead to falls and, consequently, fractures or other injuries. For patients with dementia, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic treatment.

5.8 Eosinophilia

Eosinophilia, defined as a blood eosinophil count of greater than 700/μL, has occurred with clozapine treatment. In clinical trials, approximately 1% of patients developed eosinophilia. Clozapine-related eosinophilia usually occurs during the first month of treatment. In some patients, it has been associated with myocarditis, pancreatitis, hepatitis (i.e., elevated liver enzymes). This is generally a self-limiting event to which the mortality in those treated with Clozapine ODT is not increased. If a patient develops fever, defined as a temperature of 38.5°C [101.3°F] or greater, and obtain a cardiac evaluation, and under close monitoring. Consider the possibility of myocarditis or cardiomyopathy in patients receiving Clozapine ODT who present with chest pain, dyspnea, persistent tachycardia at rest, palpitations, fever, flu-like symptoms, hypotension, other signs or symptoms of heart failure, or electrocardiographic findings (low voltages, ST-T abnormalities, arrhythmias, right axis deviation, and poor R wave progression). Myocarditis most frequently presents within the first two months of clozapine treatment. Symptoms of cardiomyopathy generally occur after several months of clozapine-associated myocarditis and usually after 8 weeks of treatment. However, myocarditis and cardiomyopathy can occur at any period during treatment with Clozapine ODT. It is common for nonspecific flu-like symptoms such as malaise, myalgia, pleuritic chest pain, and low-grade fevers to precede more overt signs of heart failure. Typical laboratory findings include elevated B-type natriuretic peptide (BNP) and highsensitivity C-reactive protein (CRP). Chest roentgenogram may demonstrate cardiac silhouette enlargement, and cardiac imaging (echocardiogram, radionuclide studies, or cardiac catheterization) may reveal evidence of left ventricular dysfunction.

5.9 QT Interval Prolongation

QT prolongation, Torsades de Pointes and other life-threatening ventricular arrhythmias, paroxysmal arrhythmia, and sudden death have occurred with clozapine treatment. When prescribing Clozapine ODT, consider the presence of additional risk factors for QT prolongation and serious cardiovascular reactions. Conditions that increase these risks include the following: history of QT prolongation, long QT syndrome, family history of sudden death or sudden cardiac death, significant cardiovascular disease, recent myocardial infarction, uncompensated heart failure, treatment with other medications that cause QT prolongation, treatment with medications that inhibit the metabolism of Clozapine ODT, and electrolyte abnormalities.

Prior to initiating treatment with Clozapine ODT, perform a careful physical examination, including an ECG, baseline and concurrent cardiovascular studies (e.g., blood pressure, heart rate, echocardiogram), and pregnancy test. Obtain a baseline ECG and serum chemistry panel. Correct electrolyte abnormalities. Discontinue Clozapine ODT if the QTc interval exceeds 500 msec. If patients experience symptoms consistent with Torsades de Pointes or other arrhythmias (e.g., syncope, presyncope, dizziness, or palpitations), obtain a cardiac evaluation and discontinue Clozapine ODT. Use caution when administering concomitant medications that prolong the QT interval or inhibit the metabolism of Clozapine ODT. Drugs that cause QT prolongation include: specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, thioridazine, mesoridazine, droperidol, pimozide), specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin), Class 1A antiarrhythmic medications (e.g.,
Table 5: Mean Changes in Total Cholesterol and Triglyceride Concentration in Studies in Adult Subjects with Schizophrenia

<table>
<thead>
<tr>
<th>Treatment Arm</th>
<th>Baseline Total Cholesterol Concentration (mg/dL)</th>
<th>Change from Baseline mg/dL (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clozapine (N=334)</td>
<td>184</td>
<td>+13 (7)</td>
</tr>
<tr>
<td>Chlorpromazine (N=185)</td>
<td>182</td>
<td>+15 (8)</td>
</tr>
<tr>
<td>Clozapine (N=6)</td>
<td>130</td>
<td>+71 (54)</td>
</tr>
<tr>
<td>Chlorpromazine (N=7)</td>
<td>110</td>
<td>+39 (35)</td>
</tr>
</tbody>
</table>

Table 6: Categorical Changes in Lipid Concentrations in Studies in Adult Subjects with Schizophrenia

<table>
<thead>
<tr>
<th>Category Change (at least once) from Baseline</th>
<th>Laboratory Parameter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increase by ( \geq 40 \text{ mg/dL} )</td>
<td>Total Cholesterol (random or fasting)</td>
</tr>
<tr>
<td>Normal (&lt;200 mg/dL to High (( \geq 240 \text{ mg/dL} ))</td>
<td>Clozapine (N=334)</td>
</tr>
<tr>
<td>Chlorpromazine (N=185)</td>
<td>182</td>
</tr>
<tr>
<td>Borderline (200 - 239 mg/dL to High (( \geq 240 \text{ mg/dL} ))</td>
<td>Clozapine (N=6)</td>
</tr>
<tr>
<td>Chlorpromazine (N=7)</td>
<td>110</td>
</tr>
<tr>
<td>Increase by ( \geq 50 \text{ mg/dL} )</td>
<td>Triglycerides (fasting)</td>
</tr>
<tr>
<td>Normal (&lt;150 mg/dL to High (( \geq 200 \text{ mg/dL} ))</td>
<td>Clozapine (N=334)</td>
</tr>
<tr>
<td>Chlorpromazine (N=185)</td>
<td>182</td>
</tr>
<tr>
<td>Borderline (150 mg/dL and &lt;200 mg/dL to High (( \geq 200 \text{ mg/dL} ))</td>
<td>Clozapine (N=6)</td>
</tr>
<tr>
<td>Chlorpromazine (N=7)</td>
<td>110</td>
</tr>
</tbody>
</table>

Table 7: Mean Change in Body Weight (kg) by duration of exposure from studies in adult subjects with schizophrenia

<table>
<thead>
<tr>
<th>Treatment Arm</th>
<th>Exposure Duration</th>
<th>Clozapine (N=669)</th>
<th>Olanzapine (N=442)</th>
<th>Chlorpromazine (N=155)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight change from baseline</td>
<td>n Mean</td>
<td>n Mean</td>
<td>n Mean</td>
<td>n Mean</td>
</tr>
<tr>
<td>2 weeks (Day 11 - 17)</td>
<td>6</td>
<td>0.9</td>
<td>3</td>
<td>0.7</td>
</tr>
<tr>
<td>4 weeks (Day 21 - 35)</td>
<td>23</td>
<td>0.7</td>
<td>8</td>
<td>0.8</td>
</tr>
<tr>
<td>8 weeks (Day 49 - 63)</td>
<td>12</td>
<td>1.9</td>
<td>13</td>
<td>1.8</td>
</tr>
<tr>
<td>12 weeks (Day 70 - 98)</td>
<td>17</td>
<td>2.8</td>
<td>5</td>
<td>3.1</td>
</tr>
<tr>
<td>24 weeks (Day 154 - 182)</td>
<td>42</td>
<td>0.6</td>
<td>14</td>
<td>0.7</td>
</tr>
<tr>
<td>48 weeks (Day 222 - 250)</td>
<td>3</td>
<td>3.7</td>
<td>3</td>
<td>13.7</td>
</tr>
</tbody>
</table>

Table 8: Proportion of adult subjects in schizophrenia studies with weight gain \( \geq 7\% \) relative to baseline body weight

<table>
<thead>
<tr>
<th>Weight Change</th>
<th>Clozapine</th>
<th>Olanzapine</th>
<th>Chlorpromazine</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>669</td>
<td>442</td>
<td>155</td>
</tr>
<tr>
<td>&gt;7% (inclusive)</td>
<td>236 (35%)</td>
<td>203 (46%)</td>
<td>13 (8%)</td>
</tr>
</tbody>
</table>

5.11 Neuroleptic Malignant Syndrome

Antipsychotics drugs including Clozapine ODT can cause a potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS). Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status, and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias). Associated findings can include elevated creatine phosphokinase (CPK), myoglobinuria, rhabdomyolysis, and acute renal failure.
The diagnostic evaluation of patients with this syndrome is complicated. It is important to consider the presence of other serious medical conditions (e.g., severe neutropenia, infection, heat stroke, primary CNS pathology, central anticholinergic toxicity, extrapyramidal symptoms, and drug fever).

The management of NMS should include (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, (2) intensive symptomatic treatment and medical monitoring, and (3) treatment of co-morbid medical conditions. There is no general agreement about specific pharmacological treatments for NMS.

If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. NMS can recur. Monitor closely if restarting treatment with antipsychotics.

NMS has occurred with clozapine monotherapy and with concomitant CNS-active medications, including lithium.

5.12 Hepatotoxicity

Severe, life-threatening, and in some cases fatal hepatotoxicity including hepatic failure, hepatic necrosis, and hepatitis have been reported in patients treated with clozapine [see Adverse Reactions (6.2)]. Monitor for the appearance of signs and symptoms of hepatotoxicity such as fatigue, malaise, anorexia, nausea, jaundice, bilirubinemia, coagulopathy, and hepatic encephalopathy. Perform serum tests for liver injury and consider permanently discontinuing treatment if hepatitis or transaminase elevations combined with other systemic symptoms are due to clozapine.

5.13 Fever

During clozapine therapy, patients have experienced transient, clozapine-related fever. The peak incidence is within the first 3 weeks of treatment. While this fever is generally benign and self-limited, it may necessitate discontinuing treatment. The fever can be associated with an increase or decrease in WBC count. Carefully evaluate patients with fever to rule out severe neutropenia or infection. Consider the possibility of NMS [see Warnings and Precautions (5.11)].

5.14 Pulmonary Embolism

Pulmonary embolism and deep vein thrombosis have occurred in patients treated with clozapine. Consider the possibility of pulmonary embolism in patients who present with deep vein thrombosis, acute dyspnea, chest pain, or with other respiratory signs and symptoms. Whether pulmonary embolus and deep vein thrombosis can be attributed to clozapine or some characteristic(s) of patients is not clear.

5.15 Anticholinergic Toxicity

Clozapine ODT has potent anticholinergic effects. Treatment with Clozapine ODT can result in CNS and peripheral anticholinergic toxicity. Use with caution in the presence of narrow-angle glaucoma, concomitant anticholinergic medications, prostatic hypertrophy, or other conditions in which anticholinergic effects can lead to significant adverse effects. Cautiously evaluate patients for sedation and monitor for other anticholinergic symptoms.

Treatment with Clozapine ODT can result in gastrointestinal adverse reactions, including constipation, intestinal obstruction, fecal impaction, and paralytic ileus. Such reactions can be fatal. Constipation should be initially treated by ensuring adequate hydration and use of ancillary therapy such as bulk laxatives. Consultation with a gastroenterologist is advisable in more serious cases.

5.16 Interference with Cognitive and Motor Performance

Clozapine ODT can cause sedation and impairment of cognitive and motor performance. Caution patients about operating hazardous machinery, including automobiles, until they are reasonably certain that Clozapine ODT does not affect them adversely. These reactions may be dose-related. Consider reducing the dose if they occur.

5.17 Tardive Dyskinesia

Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs, including Clozapine ODT. The syndrome consists of potentially irreversible, involuntary, dyskinetic movements of the face, tongue, oropharynx, trunk, or extremities that usually occur after the drug is discontinued. The risk of experiencing TD becomes irreversible after stopping treatment. Although the risk of TD is increased by concomitant neuroleptic use, it is not predictable which patients will develop the syndrome. Therefore, all antipsychotic treatment should be examined on an individual basis.

5.18 Patients with Phenylketonuria

Phenylketonuric patients should be informed that Clozapine ODT contains phenylalanine (a component of aspartame). Each 100 mg, orally disintegrating tablet contains 0.87 mg phenylalanine. Each 25 mg, orally disintegrating tablet contains 0.22 mg phenylalanine. Each 150 mg, orally disintegrating tablet contains 1.0 mg phenylalanine. Each 50 mg, orally disintegrating tablet contains 0.35 mg phenylalanine.

5.19 Cerebrovascular Adverse Reactions

In controlled trials, elderly patients with dementia-related psychosis treated with some atypical antipsychotics had an increased risk (compared to placebo) of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack), including fatalities. The mechanism for this increased risk is not known. An increased risk cannot be attributed to Clozapine ODT or other antipsychotics or other patient populations. Clozapine ODT should be used with caution in patients with risk factors for cerebrovascular adverse reactions.

5.20 Recurrence of Psychosis and Cholinergic Rebound after AbruPT Discontinuation of Clozapine ODT

If abrupt discontinuation of Clozapine ODT is necessary (because of severe neutropenia or another medical condition, for example) [see Dosage and Administration (2.4), Warnings and Precautions (5.1)], monitor carefully for the recurrence of psychotic symptoms and adverse reactions related to cholinergic rebound, such as profuse salivation, headache, nausea, vomiting, and diarrhea.

6 ADVERSE REACTIONS

The following adverse reactions are discussed in more detail in other sections of the labeling:

- Severe Neutropenia [see Warnings and Precautions (5.1)].
- Orthostatic Hypotension, Bradycardia, and Syncope [see Warnings and Precautions (5.3)].
- Fails [see Warnings and Precautions (5.4)].
- Seizures [see Warnings and Precautions (5.5)].
- Myocarditis and Cardiomyopathy [see Warnings and Precautions (5.6)].
- Increased Mortality in Elderly Patients with Dementia-Related Psychosis [see Warnings and Precautions (5.7)].
- Eosinophilia [see Warnings and Precautions (5.8)].
- QT Interval Prolongation [see Warnings and Precautions (5.9)].
- Metabolic Changes (Hyperglycemia and Diabetes Mellitus, Dyslipidemia, and Weight Gain) [see Warnings and Precautions (5.10)].
- Neuropletic Malignant Syndrome [see Warnings and Precautions (5.11)].
- Hepatotoxicity [see Warnings and Precautions (5.12)].
- Fever [see Warnings and Precautions (5.13)].
- Pulmonary Embolism [see Warnings and Precautions (5.14)].
- Anticholinergic Toxicity [see Warnings and Precautions (5.15)].
- Interference with Cognitive and Motor Performance [see Warnings and Precautions (5.16)].
- Tardive Dyskinesia [see Warnings and Precautions (5.17)].
- Patients with Phenylketonuria [see Warnings and Precautions (5.18)].
- Cerebrovascular Adverse Reactions [see Warnings and Precautions (5.19)].
- Recurrence of Psychosis and Cholinergic Rebound after AbruPT Discontinuation [see Warnings and Precautions (5.20)].

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The most commonly reported adverse reactions (≥5%) across clozapine clinical trials were: CNS reactions, including sedation, dizziness/vertigo, headache, and tremor; cardiovascular reactions, including tachycardia, hypotension, and syncope; autonomic nervous system reactions, including hypersalivation, sweating, dry mouth, and visual disturbances; gastrointestinal reactions, including constipation and nausea; and fever. Table 9 summarizes the most commonly reported adverse reactions (≥5%) in clozapine-treated patients (compared to chlorpromazine-treated patients) in the pivotal, 6-week, controlled trial in treatment-resistant schizophrenia.

Table 9: Common Adverse Reactions (≥5%) in the 6-Week, Randomized, Chlorpromazine-controlled Trial in Treatment-Resistant Schizophrenia

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>Clozapine (N=126) (%)</th>
<th>Chlorpromazine (N=142) (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sedation</td>
<td>21</td>
<td>13</td>
</tr>
<tr>
<td>Hypotension</td>
<td>17</td>
<td>11</td>
</tr>
<tr>
<td>Constipation</td>
<td>16</td>
<td>12</td>
</tr>
<tr>
<td>Dizziness</td>
<td>14</td>
<td>16</td>
</tr>
<tr>
<td>Hypersalivation</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>Hypertension</td>
<td>12</td>
<td>5</td>
</tr>
<tr>
<td>Headache</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Nausea/vomiting</td>
<td>10</td>
<td>12</td>
</tr>
<tr>
<td>Dry mouth</td>
<td>5</td>
<td>20</td>
</tr>
</tbody>
</table>

Table 10 summarizes the adverse reactions reported in clozapine-treated patients at a frequency of 2% or greater across all clozapine studies (excluding the 2-year InterSePT™ Study). These rates are not adjusted for duration of exposure.

Table 10: Adverse Reactions (≥ 2%) Reported in Clozapine-treated Patients (N=842) across all Clozapine Studies (excluding the 2-year InterSePT™ Study)

<table>
<thead>
<tr>
<th>Body System</th>
<th>Adverse Reaction</th>
<th>Clozapine N=842 Percentage of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central Nervous System</td>
<td>Drowsiness/Sedation</td>
<td>39</td>
</tr>
<tr>
<td></td>
<td>Dizziness/Vertigo</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>Headache</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Tremor</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>Syncope</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>Disturbed Sleep/Nightmares</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Restlessness</td>
<td>4</td>
</tr>
</tbody>
</table>

continued
7.2 Potential for Clozapine ODT to Affect Other Drugs

Clozapine is a substrate for many cytochrome P450 isozymes, in particular CYP1A2, CYP3A4, and CYP2D6. Use caution when administering Clozapine ODT concomitantly with drugs that are inducers or inhibitors of these enzymes.

CYP1A2 Inhibitors

Concomitant use of Clozapine ODT and CYP1A2 inhibitors can increase plasma levels of clozapine, potentially resulting in adverse reactions. Reduce the Clozapine ODT dose to one third of the original dose when Clozapine ODT is coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, or enoxacin). The Clozapine ODT dose should be increased to the original dose when coadministration of strong CYP1A2 inhibitors is discontinued [see Dosage and Administration (2.7)].

CYP2D6 and CYP3A4 Inhibitors

Concomitant treatment with Clozapine ODT and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, esomeprazole, erythromycin, paroxetine, and other specific antibiotics) can increase Clozapine ODT levels and lead to adverse reactions [see Clinical Pharmacology (12.3)]. Use caution and monitor patients closely when using such inhibitors. Consider reducing the Clozapine ODT dosage if necessary [see Dosage and Administration (2.7)].

CYP1A2 and CYP3A4 Inducers

Concomitant treatment with drugs that induce CYP1A2 or CYP3A4 can decrease the concentration of clozapine, resulting in decreased effectiveness of Clozapine ODT. Tobacco smoke is a moderate inducer of CYP1A2. Strong CYP3A4 inducers include carbamazepine, phenytoin, rifampin, and rifabutin. Use caution when administering Clozapine ODT concomitantly with CYP3A4 inducers [see Dosage and Administration (2.7)].

7.3 Drug Interactions

Use caution when administering concomitant medications that prolong the QT interval or inhibit the metabolism of Clozapine ODT. Drugs that cause QT prolongation include: specific antiparasitics (e.g., ivermectin or mebendazole), specific antibiotics (e.g., erythromycin, metronidazole, ciprofloxacin, or clarithromycin), and Class IA antiarrhythmics. Use caution when administering Clozapine ODT concomitantly with any of these agents.

7.4 Monitoring Laboratory Tests

Monitor patients closely when Clozapine ODT is coadministered with these inhibitors. Consider reducing the Clozapine ODT dosage if necessary [see Dosage and Administration (2.7)].

CYP2D6 and CYP3A4 Inducers

Concomitant treatment with Clozapine ODT and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, esomeprazole, erythromycin, paroxetine, and other specific antibiotics) can increase Clozapine ODT levels and lead to adverse reactions [see Clinical Pharmacology (12.3)]. Use caution and monitor patients closely when using such inhibitors. Consider reducing the Clozapine ODT dosage if necessary [see Dosage and Administration (2.7)].

CYP1A2 and CYP3A4 Inducers

Concomitant treatment with drugs that induce CYP1A2 or CYP3A4 can decrease the concentration of clozapine, resulting in decreased effectiveness of Clozapine ODT. Tobacco smoke is a moderate inducer of CYP1A2. Strong CYP3A4 inducers include carbamazepine, phenytoin, rifampin, and rifabutin. Use caution when administering Clozapine ODT concomitantly with CYP3A4 inducers [see Dosage and Administration (2.7)].

Consider reducing the Clozapine ODT dosage when discontinuing coadministered enzyme inducers, because discontinuation of inducers can result in increased clozapine plasma levels and an increased risk of adverse reactions [see Dosage and Administration (2.7)].

7.5 Drugs That Cause QT Interval Prolongation

Use caution when administering concomitant medications that prolong the QT interval or inhibit the metabolism of Clozapine ODT. For a complete list of drugs that cause QT prolongation, see Table 12. Drugs that cause QT prolongation include: specific antiparasitics (e.g., ivermectin or mebendazole), specific antibiotics (e.g., erythromycin, metronidazole, ciprofloxacin, or clarithromycin), and Class IA antiarrhythmics. Use caution when administering Clozapine ODT concomitantly with any of these agents.

7.6 Monitoring Laboratory Tests

Concomitant use of Clozapine ODT with drugs metabolized by CYP2D6 can increase levels of these CYP2D6 substrates. Use caution when coadministering Clozapine ODT with other drugs that are metabolized by CYP2D6. It may be necessary to use lower doses of such drugs than usually prescribed. Such drugs include specific antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide).

7.7 Potential for Clozapine ODT to Affect Other Drugs

Concomitant use of Clozapine ODT with other drugs metabolized by CYP2D6 can increase levels of these CYP2D6 substrates. Use caution when coadministering Clozapine ODT with other drugs that are metabolized by CYP2D6. It may be necessary to use lower doses of such drugs than usually prescribed. Such drugs include specific antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide).

7.8 Potential for Other Drugs to Affect Clozapine ODT

Clozapine is a substrate for many cytochrome P450 isozymes, in particular CYP1A2, CYP3A4, and CYP2D6. Use caution when administering Clozapine ODT concomitantly with drugs that are inducers or inhibitors of these enzymes.

CYP1A2 Inhibitors

Concomitant use of Clozapine ODT and CYP1A2 inhibitors can increase plasma levels of clozapine, potentially resulting in adverse reactions. Reduce the Clozapine ODT dose to one third of the original dose when Clozapine ODT is coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, or enoxacin). The Clozapine ODT dose should be increased to the original dose when coadministration of strong CYP1A2 inhibitors is discontinued [see Dosage and Administration (2.7)].

CYP2D6 and CYP3A4 Inhibitors

Concomitant treatment with Clozapine ODT and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, esomeprazole, erythromycin, paroxetine, and other specific antibiotics) can increase Clozapine ODT levels and lead to adverse reactions [see Clinical Pharmacology (12.3)]. Use caution and monitor patients closely when using such inhibitors. Consider reducing the Clozapine ODT dosage if necessary [see Dosage and Administration (2.7)].

CYP1A2 and CYP3A4 Inducers

Concomitant treatment with drugs that induce CYP1A2 or CYP3A4 can decrease the concentration of clozapine, resulting in decreased effectiveness of Clozapine ODT. Tobacco smoke is a moderate inducer of CYP1A2. Strong CYP3A4 inducers include carbamazepine, phenytoin, rifampin, and rifabutin. Use caution when administering Clozapine ODT concomitantly with CYP3A4 inducers [see Dosage and Administration (2.7)].

Consider reducing the Clozapine ODT dosage when discontinuing coadministered enzyme inducers, because discontinuation of inducers can result in increased clozapine plasma levels and an increased risk of adverse reactions [see Dosage and Administration (2.7)].

Consider reducing the Clozapine ODT dosage when discontinuing coadministered enzyme inducers, because discontinuation of inducers can result in increased clozapine plasma levels and an increased risk of adverse reactions [see Dosage and Administration (2.7)].
CLOzapine ODT (Orally Disintegrating Tablets) for oral use

10 OVERDOSAGE
10.2 Management of Overdosage
For the most up-to-date information on the management of Clozapine ODT overdosage, contact a certified Regional Poison Control Center (1-800-222-1222). Telephone numbers of certified Regional Poison Control Centers are listed in the Physicians' Desk Reference®, a registered trademark of PDR Network. Establish and maintain an airway; ensure adequate oxygenation and ventilation. Monitor cardiac status and vital signs. Use general supportive and symptomatic measures. There are no specific antidotes for Clozapine ODT. In managing overdosage, consider the possibility of multiple-drug involvement.

11 DESCRIPTION
Clozapine ODT, an atypical antipsychotic drug, is a tricyclic dibenzodiazepine derivative, 5-chloro-11-((4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine. The structural formula is:

C8H19ClN4  Mol. wt. 326.83

Clozapine ODT is available as yellow, orally disintegrating tablets of 12.5 mg, 25 mg, 100 mg, 150 mg and 200 mg for oral administration without water. Clozapine ODT may be chewed.

Each orally disintegrating tablet contains clozapine equivalent to 12.5 mg, 25 mg, 100 mg, 150 mg and 200 mg.

The active component of Clozapine ODT is clozapine. The remaining components are aspartame, microcrystallite cellulose, lactose, calcium sulfate, magnesium stearate, and natural and artificial mint flavor, sodium bicarbonate, citric acid, ferric oxide (yellow), and magnesium stearate.

1.25, 25, and 100 mg tablets

*150 and 200 mg tablets

THIS PRODUCT CONTAINS ASPARTAME AND IS NOT INTENDED FOR USE BY INFANTS.

12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
The mechanism of action of clozapine is unknown. However, it has been proposed that the therapeutic efficacy of clozapine in schizophrenia is mediated through antagonism of the dopamine type 2 (D2) and the serotonin type 2A (5-HT2A) receptors. Clozapine ODT also acts as an antagonist at adrenergic, cholinergic, histaminergic and other dopaminergic and serotoninergic receptors.

12.2 Pharmacodynamics
Clozapine demonstrated binding affinity to the following receptors: histamine H1, (K_D of 230 nM), adrenergic a1 (K_D of 10 nM), serotonin 5-HT1 (K_D of 1.6 nM), serotonin 5-HT2A (K_D of 5.4 nM), muscarinic M1 (K_D of 5 nM), serotonin 5-HT3 (K_D of 20 nM), serotonin 5-HT5 (K_D of 1.6 nM), dopamine D1 (K_D of 24 nM), adrenergic a2 (K_D of 90 nM), serotonin 5-HT6 (K_D of 10 nM), serotonin 5-HT7 (K_D of 10 nM), dopamine D2 (K_D of 160 nM), dopamine D3 (K_D of 270 nM), dopamine D4 (K_D of 454 nM), and dopamine D5 (K_D of 555 nM).

Clozapine causes little or no prolactin elevation.

Clinical electroencephalogram (EEG) studies demonstrated that clozapine increases delta and theta activity and slows dominant alpha frequencies. Enhanced synchronization occurs. Sharp wave activity and spike and wave complexes may also develop. Patients have reported an intensification of dream activity during clozapine therapy. REM sleep has been increased to 80% of the total sleep time. In these patients, the onset of REM sleep occurred almost immediately after falling asleep.

12.3 Pharmacokinetics
Absorption
In man, clozapine tablets (25 mg and 100 mg) are equally bioavailable relative to a clozapine solution. Clozapine ODT is bioequivalent to Clozaril® (clozapine) tablets, a registered trademark of Novartis Pharmaceuticals Corporation. Following a dosage of 100 mg b.i.d., the average steady-state peak plasma concentration was 413 ng/mL (range: 132-854 ng/mL), occurring at the average of 2.3 hours (range: 1.6-6 hours) after dosing. The average minimum concentration at steady-state was 168 ng/mL (range: 45-574 ng/mL), after 100 mg b.i.d. dosing.

A comparative bioequivalence/bioavailability study was conducted in 28 patients (with schizophrenia or schizoaffective disorder) comparing FazaClo® 200 mg tablets to 2 × FazaClo® 100 mg tablets (the approved reference product) under fasted conditions. The study also evaluated the effect of food and chewing on the pharmacokinetics of the 200 mg tablet. Under fasted conditions, the mean AUC and Cmax of clozapine for the 200 mg tablets were equivalent to those of the 2 × 100 mg tablets. The mean Cmax of clozapine for FazaClo® 200 mg tablets was 85% that for 2 × 100 mg FazaClo® tablets. This decrease in Cmax for FazaClo® 200 mg tablets is not clinically significant.
CLOZAPINE ODT (Orally Disintegrating Tablets) for oral use

For FazaClo® 200 mg tablets, food significantly increased the Cmin,ss of clozapine by approximately 20%, compared to administration under fasting conditions, while the AUCss and Cmax,ss values were similar between the chewed and non-chewed conditions. For FazaClo® 200 mg tablets, food significantly increased the Cmin,ss of clozapine by 21%. However, this increase is not clinically significant. The mean Cmin,ss and Cmax,ss of clozapine under fed conditions were equivalent to those under fasted conditions. Food delayed clozapine absorption by 1.5 hours, from a median T1/2 of 2.5 hours under fasted conditions to 4 hours under fed conditions.

The mean Cmax,ss of clozapine under chewed conditions for FazaClo® 200 mg tablets was about 80% of the mean Cmax,ss for FazaClo® tablets under non-chewed conditions, while the AUC,ss and Cmax,ss values were similar between the chewed and non-chewed conditions.

In a food-effect study, a single dose of FazaClo® (clozapine) orally disintegrating tablets 12.5 mg was administered to healthy volunteers under fasting conditions and after a light meal. When FazaClo® was administered after a high fat meal, the Cmin of both clozapine and its active metabolite, desmethyloclozapine, were decreased by approximately 20%, compared to administration under fasting conditions, while the AUC values were unchanged. This decrease in Cmin is not clinically significant. Therefore, Clozapine orally disintegrating tablets can be taken without regard to meals.

Clozapine is approximately 97% bound to serum proteins. The interaction between clozapine and other highly protein-bound drugs has not been fully evaluated but may be important [see Drug Interactions (7)].

Metabolism and Excretion

Clozapine is almost completely metabolized prior to excretion, and only trace amounts of unchanged drug are detected in the urine and feces. Clozapine is a substrate for many cytochrome P450 isozymes, in particular CYP1A2, CYP2D6, and CYP3A4. Approximately 50% of the administered dose is excreted in the urine and 30% in the feces. The measured metabolites in clozapine and clozapine N-oxide derivatives were inactive. The mean elimination half-life of clozapine after a single 75 mg dose was 8 hours (range: 4–12 hours), compared to a mean elimination half-life of 12 hours (range: 4-66 hours), after achieving steady-state with 100 mg twice daily dosing. A comparison of single-dose and multiple-dose administration of clozapine demonstrated that the elimination half-life increased significantly after multiple dosing relative to that after single-dose administration, suggesting the possibility of concentration-dependent pharmacokinetics. However, at steady-state, approximately dose-proportional changes with respect to AUC (area under the curve), peak, and minimum clozapine plasma concentrations were observed after administration of 37.5, 75, and 150 mg twice daily.

Drug-Drug Interaction Studies

A pharmacokinetic study was conducted in 16 schizophrenic patients who received clozapine under steady-state conditions. After coadministration of fluvoxamine for 14 days, mean trough concentrations of clozapine and its metabolites, N-desmethyloclozapine and clozapine N-oxide, were elevated about three-fold compared to baseline steady-state concentrations. Paroxetine, Fluoxetine, and Sertraline

In a study of schizophrenic patients (n=14) who received clozapine under steady-state conditions, coadministration of paroxetine produced only minor changes in the levels of clozapine and its metabolites. However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations. Other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations.

Specific Population Studies

Renal or Hepatic Impairment

In specific pharmacokinetics studies were conducted to investigate the effects of renal or hepatic impairment on the pharmacokinetics of clozapine. Higher clozapine plasma concentrations are likely in patients with significant renal or hepatic impairment when given usual doses. CYP2D6 Poor Metabolizers

A subset (3%–10%) of the population has reduced activity of CYP2D6 (CYP2D6 Poor Metabolizers). These individuals may develop higher than expected plasma concentrations of clozapine when given usual doses.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

No carcinogenic potential was demonstrated in long-term studies in mice and rats at doses up to 0.3 times and 0.4 times, respectively, the maximum recommended human dose (MRHD) of 900 mg/day on a mg/m² body surface area basis.

Mutagenesis

Clozapine was not genotoxic when tested in the following gene mutation and chromosomal aberration tests: the bacterial Ames test, the in vitro mammalian V79 in Chinese hamster cells, the in vitro unscheduled DNA synthesis in rat hepatocytes, or the in vivo micronucleus assay in mice.

Impairment of Fertility

Clozapine had no effect on any parameters of fertility, pregnancy, fetal weight, or postnatal development when administered orally to male rats 70 days before mating and to female rats for 14 days before mating at doses up to 0.4 times the MRHD of 900 mg/day on a mg/m² body surface area basis.

14 CLINICAL STUDIES

14.1 Treatment-Resistant Schizophrenia

The efficacy of clozapine in treatment-resistant schizophrenia was established in a multicenter, randomized, double-blind, active-controlled (chlorpromazine) study in patients with a DSM-III diagnosis of schizophrenia who had inadequate responses to at least 3 different antipsychotics (from at least 2 different chemical classes) during the preceding 5 years. The antipsychotic trials must have been judged adequate; the antipsychotic dosages must have been sufficient or greater than 1000 mg per day of chlorpromazine for a period of at least 6 weeks, each without significant reduction of symptoms. There must have been no period of good functioning within the preceding 5 years. Patients must have had at least 45 on the investigator-rated Brief Psychiatric Rating Scale (BPRS). On the 18-item BPRS, 1 indicates the absence of symptoms, and 7 indicates severe symptoms; the maximum potential total BPRS score is 126. At baseline, the mean BPRS score was 61. In addition, patients must have had a score of at least 4 on at least two of the following four individual BPRS items: conceptual disorganization, hallucinatory behavior, unusual thought content. Patients must have had a Clinical Global Impressions – Severity Scale score of at least 4 (moderately ill).

In the prospective, lead-in phase of the trial, all patients (N=305) initially received single-blind treatment with haloperidol (the mean dose was 12.5 mg/day per week) for 4 weeks. More than 80% of patients completed the 4-week trial. Patients with an inadequate response to haloperidol (N=268) were randomized to double-blind treatment with clozapine (N=126) or chlorpromazine (N=142). The maximum daily clozapine dose was 900 mg; the mean daily dose was 600 mg. The maximum daily chlorpromazine dose was 1800 mg; the mean daily dose was 1200 mg. The primary endpoint was treatment response, predefined as a decrease in BPRS score of at least 20% and either (1) a CGI-S score of 3 (mildly ill), or (2) a BPRS score of 35, at the end of 6 weeks of treatment. Approximately 88% of patients from the clozapine and chlorpromazine groups completed the 6-week trial. At the end of six weeks, 30% of patients on clozapine and 14% of patients on chlorpromazine responded to treatment. The difference was statistically significant (p<0.001). The mean change in total BPRS score was -16 and -5 in the clozapine and chlorpromazine group, respectively; the mean change in the 4 key BPRS item scores was -5 and -2 in the clozapine and chlorpromazine group, respectively, and the mean change in CGI-S severity was -2.5 and -1.2 in the clozapine and chlorpromazine group, respectively. These changes in the clozapine group were statistically significantly greater than in the chlorpromazine group (p<0.001 in each analysis).

14.2 Recurrent Suicidal Behavior in Schizophrenia or Schizoaffective Disorder

The effectiveness of clozapine in reducing the risk of recurrent suicidal behavior was assessed in the International Suicide Prevention Trial (InterSePT, a trademark of Novartis Pharmaceuticals Corporation). This was a prospective, randomized, open-label, active-controlled, multicenter, international, parallel-group comparison of clozapine (Clozaril®) versus olanzapine (Zyprexa®, a registered trademark of Eli Lilly and Company) in 956 patients with schizophrenia or schizoaffective disorder (DSM-IV) who were judged to be at high risk for current suicidal behavior. One in four of these patients (27%) were considered resistant to standard antipsychotic drug treatment. To enter the trial, patients must have met one of the following criteria:

- They had attempted suicide within the three years prior to their baseline evaluation.
- They had been hospitalized to prevent a suicide attempt within the three years prior to their baseline evaluation.
- They demonstrated moderate-to-severe suicidal ideation with a depressive component within one week prior to their baseline evaluation.
- They demonstrated moderate-to-severe suicidal ideation accompanied by command hallucinations to do self-harm within one week prior to their baseline evaluation.

Dosing: A total of 980 patients were randomized to the study and 956 received study medication. Dosing was flexible, with a dose range of 200–900 mg/day for clozapine and 5–20 mg/day for olanzapine. For the 956 patients who received clozapine or olanzapine in this study, there was extensive use of concomitant psychotropic medications among the patients in the olanzapine group.

The primary efficacy measure was time to (1) a significant suicide attempt, including a completed suicide; (2) hospitalization due to imminent suicide risk, including increased level of surveillance for suicidality for patients already hospitalized; or (3) worsening of suicidality severity as demonstrated by “much worsening” or “very much worsening” from baseline in the Clinical Global Impressions of Severity of Suicidality as assessed by the Blinded Interpreter (GSI-SB-IP). A total of 980 patients were randomized to the study and 956 received study medication. Sixty-two percent of the patients were diagnosed with schizophrenia, and the remainder (38%) were diagnosed with schizoaffective disorder. Only about one-fourth of the total patient population (27%) was considered resistant to standard antipsychotic drug treatment.

The probability of experiencing (1) a significant suicide attempt, including a completed suicide, or (2) hospitalization because of imminent suicide risk, including increased level of surveillance for suicidality for patients already hospitalized, was lower for clozapine patients than for olanzapine patients at Week 104: clozapine 24% versus olanzapine 32%; 95% CI of the difference: 2%, 14% (Figure 1).
CLOZAPINE ODT (Orally Disintegrating Tablets) for oral use

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

12.5 mg
1/4-inch diameter round yellow tablet debossed with “A05” on one side.
Bottles of 100:
100 tablets in an HDPE bottle with child-resistant cap. …………..NDC No. 0093-3011-01
25 mg
5/16-inch diameter round yellow tablet debossed with “A06” on one side.
Bottles of 100:
100 tablets in an HDPE bottle with child-resistant cap. …………..NDC No. 0093-3012-01
Cartons of 48 for Institutional Use Only:
8 cards, 6 non child-resistant blisters per card. ………………….. NDC No. 0093-3012-84
100 mg
1/2-inch diameter round yellow tablet debossed with “A08” on one side.
Bottles of 100:
100 tablets in an HDPE bottle with child-resistant cap. …………..NDC No. 0093-3010-01
Cartons of 48 for Institutional Use Only:
8 cards, 6 non-child-resistant blisters per card. ………………….. NDC No. 0093-3010-84
150 mg
9/16-inch diameter round, yellow tablet debossed with “A09” on one side.
Bottles of 100:
100 tablets in an HDPE bottle with child-resistant cap. …………..NDC No. 0093-3086-01
Cartons of 48 for Institutional Use Only:
8 cards, 6 non-child-resistant blisters per card. ………………….. NDC No. 0093-3086-84
200 mg
5/8-inch diameter round, yellow tablet debossed with “A10” on one side.
Bottles of 100:
100 tablets in an HDPE bottle with child-resistant cap. …………..NDC No. 0093-3087-01
Cartons of 48 for Institutional Use Only:
8 cards, 6 non-child-resistant blisters per card. ………………….. NDC No. 0093-3087-84

16.2 Storage and Handling

Store Clozapine ODT at 20°C to 25°C (68° to 77°F); excursions permitted to 15°C to 30°C (59° to 86°F). (See USP Controlled Room Temperature.) Protect from moisture. KEEP OUT OF REACH OF CHILDREN.

Clozapine ODT must remain in the original package until used by the patient.

Drug dispensing should not ordinarily exceed a weekly supply. If a patient is eligible for ANC testing every 4 weeks, then a 4-week supply of Clozapine ODT should be dispensed. If a patient is eligible for ANC testing every 4 weeks, then a 4-week supply of Clozapine ODT can be dispensed. Dispensing should be contingent upon the ANC testing results.

17 PATIENT COUNSELING INFORMATION

Discuss the following issues with patients and caregivers:

Severe Neutropenia:
- Instruct patients and caregivers: Patients and caregivers should be instructed to immediately report to their physician any symptom or sign of neutropenia (e.g., fever, pain, sore throat, skin rash, jaw pain, or other signs or symptoms suggestive of infection).

QT Interval Prolongation:
- Instruct patients and caregivers: Patients and caregivers should be instructed to immediately report to their physician if they feel faint, lose consciousness, or have signs or symptoms suggestive of arrhythmia.

Interstitial Lung Disease:
- Instruct patients and caregivers: Patients and caregivers should be instructed to immediately report to their physician if they have signs or symptoms suggestive of respiratory symptoms.

Interference with Cognitive and Motor Performance:
- Instruct patients and caregivers: Patients and caregivers should be instructed to immediately report to their physician if they feel faint, lose consciousness, or have signs or symptoms suggestive of syncope.

High Risk of Suicidality
- Instruct patients and caregivers: Patients and caregivers should be instructed to immediately report to their physician any symptom or sign of suicidality.

Orthostatic Hypotension, Bradycardia, and Syncope:
- Instruct patients and caregivers: Patients and caregivers should be instructed to immediately report to their physician if they feel faint, lose consciousness, or have signs or symptoms suggestive of orthostatic hypotension.

Hepatotoxicity:
- Instruct patients and caregivers: Patients and caregivers should be instructed to immediately report to their physician if they have signs or symptoms suggestive of hepatotoxicity.

Missed Doses and Re-Initiating Treatment:
- Instruct patients and caregivers: Patients and caregivers should be instructed to immediately report to their physician if they have missed taking Clozapine ODT for more than 2 days.

Pregnancy:
- Instruct patients and caregivers: Patients and caregivers should be instructed to immediately report to their physician if they are pregnant or intend to become pregnant during therapy.

Lactation:
- Instruct patients and caregivers: Patients and caregivers should be instructed to immediately report to their physician if they are breastfeeding.

Table 1:
- Instruct patients and caregivers: Patients and caregivers should be instructed to immediately report to their physician if they have signs or symptoms suggestive of jaundice, bilirubinemia, coagulopathy, and hepatic encephalopathy.

Patients with Phenylketonuria:
- Instruct patients and caregivers: Patients and caregivers should be instructed to immediately report to their physician if they have signs or symptoms suggestive of hyperglycemia.

Patients with Diabetes Mellitus:
- Instruct patients and caregivers: Patients and caregivers should be instructed to immediately report to their physician if they have signs or symptoms suggestive of diabetes mellitus.

Patients with Seizures:
- Instruct patients and caregivers: Patients and caregivers should be instructed to immediately report to their physician if they have signs or symptoms suggestive of seizures.

Patients with QT Interval Prolongation:
- Instruct patients and caregivers: Patients and caregivers should be instructed to immediately report to their physician if they have signs or symptoms suggestive of QT interval prolongation.

 Patients with Interference with Cognitive and Motor Performance:
- Instruct patients and caregivers: Patients and caregivers should be instructed to immediately report to their physician if they have signs or symptoms suggestive of interference with cognitive and motor performance.

Patients with High Risk of Suicidality:
- Instruct patients and caregivers: Patients and caregivers should be instructed to immediately report to their physician if they have signs or symptoms suggestive of high risk of suicidality.

Patients with Orthostatic Hypotension, Bradycardia, and Syncope:
- Instruct patients and caregivers: Patients and caregivers should be instructed to immediately report to their physician if they have signs or symptoms suggestive of orthostatic hypotension, bradycardia, and syncope.

Patients with Hepatotoxicity:
- Instruct patients and caregivers: Patients and caregivers should be instructed to immediately report to their physician if they have signs or symptoms suggestive of hepatotoxicity.

Patients with Missed Doses and Re-Initiating Treatment:
- Instruct patients and caregivers: Patients and caregivers should be instructed to immediately report to their physician if they have signs or symptoms suggestive of missed doses and re-initiating treatment.

Patients with Pregnancy:
- Instruct patients and caregivers: Patients and caregivers should be instructed to immediately report to their physician if they have signs or symptoms suggestive of pregnancy.

Patients with Lactation:
- Instruct patients and caregivers: Patients and caregivers should be instructed to immediately report to their physician if they have signs or symptoms suggestive of lactation.

Table 1:
- Instruct patients and caregivers: Patients and caregivers should be instructed to immediately report to their physician if they have signs or symptoms suggestive of Table 1.

Interfering with Cognitive and Motor Performance:
- Instruct patients and caregivers: Patients and caregivers should be instructed to immediately report to their physician if they have signs or symptoms suggestive of Interfering with Cognitive and Motor Performance.

High Risk of Suicidality:
- Instruct patients and caregivers: Patients and caregivers should be instructed to immediately report to their physician if they have signs or symptoms suggestive of High Risk of Suicidality.

Table 2:
- Instruct patients and caregivers: Patients and caregivers should be instructed to immediately report to their physician if they have signs or symptoms suggestive of Table 2.

Interference with Cognitive and Motor Performance:
- Instruct patients and caregivers: Patients and caregivers should be instructed to immediately report to their physician if they have signs or symptoms suggestive of Interference with Cognitive and Motor Performance.
CLOZAPINE ORALLY DISINTEGRATING TABLETS

WARNING: SEVERE NEUTROPENIA; ORTHOSTATIC HYPOTENSION, BRADYCARDIA, AND SYCONE; SEIZURE; MYOCARDITIS AND CARDIOMYOPATHY; INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

See full prescribing information for complete boxed warning.

- Severe Neutropenia: Clozapine can cause severe neutropenia, which can lead to serious and fatal infections. Patients initiating and continuing treatment with clozapine must have a baseline blood absolute neutrophil count (ANC) measured before treatment initiation and regular ANC monitoring during treatment. (2.1, 5.1)
- Clozapine is available only through a restricted program called the Clozapine REMS. (5.2)
- Orthostatic Hypotension, Bradycardia, and Syncope: Risk is dose-related. Starting dose is 12.5 mg. Titrate gradually and use divided dosages. (2.2, 2.6, 5.3)
- Seizure: Risk is dose-related. Titrate gradually and use divided doses. Use with caution in patients with history of seizure or risk factors for seizure. (2.2, 5.5)
- Myocarditis and Cardiomyopathy: Can be fatal. Discontinue and obtain cardiac evaluation if findings suggest these cardiac reactions. (5.6)
- Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Clozapine is not approved for this condition. (5.7)

--- RECENT MAJOR CHANGES ---

- Warnings and Precautions. Falls (5.4), Hepatotoxicity (5.12) 02/2017

INSTRUCTIONS AND USAGE

Clozapine orally disintegrating tablets are an atypical antipsychotic indicated for:

- Treatment-resistant schizophrenia. Efficacy was established in an active-controlled study. (1.1, 14.1)
- Reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder. Efficacy was established in an active-controlled study. (1.2, 14.2)

DOSAGE AND ADMINISTRATION

- Starting Dose: 12.5 mg once daily or twice daily. (2.3)
- Use caution titration and divided dosage schedule. (2.3, 5.3)
- Titration: increase the total daily dosage in increments of 25 mg to 50 mg per day, depending on the degree of response. (2.3)
- Target dose: 300 mg to 450 mg per day, in divided doses, by the end of 2 weeks. (2.3)
- Subsequent increases: increase in increments of 100 mg or less, once or twice weekly. (2.3)
- Maximum daily dose: 900 mg (2.3)
- Tablets rapidly disintegrate after placement in the mouth and may be chewed if desired. No water is needed (2.3).

DOSAGE FORMS AND STRENGTHS

Orally disintegrating tablets: 25 mg and 100 mg (3)

CONTRAINDICATIONS

Known serious hypersensitivity to clozapine or any other component of clozapine orally disintegrating tablets (4.1)

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

1.1 Treatment-Resistant Schizophrenia
1.2 Reduction in the Risk of Recurrent Suicidal Behavior in Schizophrenia or Schizoaffective Disorder

2 DOSAGE AND ADMINISTRATION

2.1 Required Laboratory Testing Prior to Initiation and During Therapy
2.2 Important Administration Instructions
2.3 Dosing Information
2.4 Maintenance Treatment
2.5 Discontinuation of Treatment
2.6 Re-Initiation of Treatment
2.7 Dosage Adjustments with Concomitant use of CYP1A2, CYP2D6, CYP3A4 Inhibitors or CYP1A2, CYP3A4 Inducers
2.8 Renal or Hepatic Impairment or CYP2D6 Poor Metabolizers

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

4.1 Hypersensitivity

5 WARNINGS AND PRECAUTIONS

5.1 Severe Neutropenia
5.2 Clozapine REMS Program
5.3 Orthostatic Hypotension, Bradycardia, and Syncope
5.4 Falls
5.5 Seizures
5.6 Myocarditis and Cardiomyopathy

6 ADVERSE REACTIONS

- Eosinophilia: Assess for organ involvement (e.g., myocarditis, pancreatitis, hepatitis, colitis, nephritis). Discontinue if these occur. (5.8)
- QT Interval Prolongation: Can be fatal. Consider additional risk factors for prolonged QT interval (disorders and drugs). (5.9)
- Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include:
  - Hyperglycemia and Diabetes Mellitus: Monitor for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Monitor glucose regularly in patients with diabetes or at risk for diabetes. (5.10)
  - Dyslipidemia: Undesirable alterations in lipids have occurred in patients treated with atypical antipsychotics. (5.10)
- Weight Gain: Significant weight gain has occurred. Monitor weight gain. (5.10)
- Neuroleptic Malignant Syndrome (NMS): Immediately discontinue and monitor closely. Assess for co-morbid conditions. (5.11)
- Hepatotoxicity: Can be fatal. Monitor for hepatotoxicity. Discontinue treatment if hepatitis or transaminase elevations combined with other symptoms occur (5.12).
- Fever: Evaluate for infection and for neutropenia, NMS. (5.13)
- Pulmonary Embolism (PE): Consider PE if respiratory distress, chest pain, or deep-vein thrombosis occur. (5.14)
- Anticholinergic Toxicity: Use cautiously in presence of specific conditions (e.g., narrow angle glaucoma, use of anticholinergic drugs). (5.15)
- Interference with Cognitive and Motor Performance: Advise caution when operating machinery, including automobiles. (5.16)

DRUG INTERACTIONS

- Concomitant use of Strong CYP1A2 Inhibitors: Reduce clozapine dose to one third when coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, enoxacin). (2.7, 7.1)
- Concomitant use of Strong CYP3A4 Inducers is not recommended. (2.7, 7.1)
- Discontinuation of CYP1A2 or CYP3A4 Inducers: Consider reducing clozapine dose when CYP1A2 (e.g., tobacco smoke) or CYP3A4 inducers (e.g., carbamazepine) are discontinued. (2.7, 7.1)

USE IN SPECIFIC POPULATIONS

- Nursing Mothers: Discontinue drug or discontinue nursing, taking into consideration importance of drug to mother. (8.3)

See 17 for PATIENT COUNSELING INFORMATION

Revised: 02/2017
INDICATIONS AND USAGE

1.1 Treatment-Resistant Schizophrenia

Clozapine orally disintegrating tablets are indicated for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the risks of severe neutropenia and of seizure associated with their use, clozapine orally disintegrating tablets should be used only in patients who have failed to respond adequately to standard antipsychotic treatment (see Warnings and Precautions (5.5)). The effectiveness of clozapine orally disintegrating tablets in treatment-resistant schizophrenia was demonstrated in a 6-week, randomized, double-blind, active-controlled study comparing clozapine orally disintegrating tablets and chlorpromazine in patients who had failed other antipsychotics (see Clinical Studies (14.1)).

1.2 Reduction in the Risk of Recurrent Suicidal Behavior in Schizophrenia or Schizoaffective Disorder

Clozapine orally disintegrating tablets are indicated for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior, based on history and recent clinical state. Suicidal behavior refers to actions by a patient that put him/herself at risk for death. The effectiveness of clozapine orally disintegrating tablets in reducing the risk of recurrent suicidal behavior was demonstrated over a two-year treatment period in the InterSePT™ trial (see Clinical Studies (14.2)).

DOSAGE AND ADMINISTRATION

2.1 Required Laboratory Testing Prior to Initiation and During Therapy

Prior to initiating treatment with clozapine orally disintegrating tablets, a baseline ANC must be obtained. The baseline ANC must be at least 1500/μL for the general population, and at least 1000/μL for patients with documented Benign Ethnic Neutropenia (BEN). To continue treatment, the ANC must be monitored regularly (see Warnings and Precautions (5.5)).

2.2 Important Administration Instructions

Clozapine orally disintegrating tablets should be immediately placed in the mouth after removing the tablet from the blister pack or bottle. The tablet disintegrates rapidly after placement in the mouth. The tablets can be allowed to disintegrate, or they may be chewed. They may be swallowed with saliva. No water is necessary for administration. The orally disintegrating tablets in a blister pack should be left in the unopened blister until the time of use. Just prior to use, peel the foil from the blister and gently remove the orally disintegrating tablet. Do not push the tablets through the foil, because this could damage the tablet.

2.3 Dosing Information

The starting dose is 12.5 mg once daily or twice daily. The total daily dose can be increased in increments of 25 mg to 50 mg per day, if well-tolerated, to achieve a target dose of 300 mg to 450 mg per day (administered in divided doses) by the end of 2 weeks. Subsequently, the dose can be increased once weekly or twice weekly, in increments of up to 100 mg. The maximum dose is 900 mg per day. To minimize the risk of orthostatic hypotension, bradycardia, and syncope, it is necessary to use this low starting dose, gradual titration schedule, and divided doses (see Warnings and Precautions (5.3)).

2.4 Maintenance Treatment

Generally, patients responding to clozapine orally disintegrating tablets should continue maintenance treatment on their effective dose beyond the acute episode.

2.5 Discontinuation of Treatment

Method of treatment discontinuation will vary depending on the patient’s last ANC:

- Table 2 or 3 for appropriate ANC monitoring based on the level of neutropenia (see Warnings and Precautions (5.5)).
- For treatment discontinuation is necessary because of moderate to severe neutropenia.
- Reduce the dose gradually over a period of 1 to 2 weeks if termination of clozapine therapy is planned and there is evidence of moderate to severe neutropenia.
- For abrupt clozapine discontinuation for a reason unrelated to neutropenia, continuation of the existing ANC monitoring is recommended for general population patients until their ANC is ≥1000/μL and for BEN patients until their ANC is ≥1000/μL, or above their baseline.
- Additional ANC monitoring is required for any patient reporting onset of fever (temperature of 38.5°C or 101.3°F, or greater) during the 2 weeks after discontinuation (see Warnings and Precautions (5.5)).
- Monitor all patients carefully for the recurrence of psychiatric symptoms and symptoms related to cholinergic rebound such as profuse sweating, headache, nausea, vomiting, and diarrhea.

2.6 Re-initiation of Treatment

When restarting clozapine orally disintegrating tablets in patients who have discontinued clozapine orally disintegrating tablets (i.e., 2 days or more since the last dose), re-initiate with 12.5 mg once daily or twice daily. This is necessary to minimize the risk of orthostatic hypotension, bradycardia, and syncope (see Warnings and Precautions (5.5)). If that dose is well-tolerated, the dose may be increased to the previously therapeutic dose more quickly than recommended for initial treatment.

2.7 Dose Adjustments with Comorbid use of CYP1A2, CYP2D6, CYP3A4 Inducers or CYP1A2, CYP3A4 Inhibitors

Dose adjustments may be necessary in patients with concomitant use of: strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, or enoxacin); moderate or weak CYP1A2 inhibitors (e.g., oral contraceptives, or caffeine); CYP2D6 or CYP3A4 inhibitors (e.g., cilostazole, clarithromycin, or diltiazem) (Table 1) (see Drug Interactions (7)).
ensure the presence of a normal baseline neutrophil count (equal to or greater than 1500/μL) is usually available as a component of the complete blood count (CBC), including the ANC value, prior to initiating treatment with clozapine to reduce the risk of neutropenia.

- **Strong CYP1A2 Inhibitors**: Use one third of the clozapine orally disintegrating tablets dose.
- **Moderate or Weak CYP1A2 Inhibitors**: Monitor for adverse reactions. Consider reducing the clozapine orally disintegrating tablets dose if necessary.
- **CYP2D6 or CYP3A4 Inhibitors**: Monitor for adverse reactions. Consider increasing the clozapine orally disintegrating tablets dose if necessary.

### 2.8 Renal or Hepatic Impairment or CYP2D6 Poor Metabolizers

It may be necessary to reduce the clozapine orally disintegrating tablets dose in patients with significant renal or hepatic impairment, or in CYP2D6 poor metabolizers (see Use in Specific Populations (8.6, 8.7)).

### 3 DOSAGE FORMS AND STRENGTHS

Clozapine Orally Disintegrating Tablets are available as 25 mg and 100 mg, round, yellow, orally disintegrating tablets.

### 4 CONTRAINDICATIONS

4.1 Hypersensitivity

Clozapine orally disintegrating tablets are contraindicated in patients with a history of serious hypersensitivity to clozapine (e.g., photosensitivity, vasculitis, erythema multiforme, or Stevens-Johnson Syndrome) or any other component of clozapine orally disintegrating tablets (see Adverse Reactions [6.2]).

### 5 WARNINGS AND PRECAUTIONS

5.1 Severe Neutropenia

#### Background

Clozapine can cause neutropenia (a low absolute neutrophil count [ANC]), defined as a reduction below pre-treatment normal levels of blood neutrophils. The ANC is usually available as a component of the complete blood count (CBC), including differential, and is more relevant to drug-induced neutropenia than is the white blood cell (WBC) count. The ANC may also be calculated using the following formula: ANC equals the total WBC count multiplied by the total percentage of neutrophils obtained from the differential (neutrophil "segs" plus neutrophil "bands"). Other granulocytes (basophils and eosinophils) contribute minimally to neutropenia and their measurement is not necessary (see Adverse Reactions [6.2]). Neutropenia may be mild, moderate, or severe (see Tables 2 and 3). To improve and standardize understanding, "severe neutropenia" replaces the previous terms severe leukopenia, severe granulocytopenia, or agranulocytosis.

Severe neutropenia, ANC less than (<) 500/μL, occurs in a small percentage of patients taking clozapine and is associated with an increase in the risk of serious and potentially fatal infections. Risk of neutropenia appears greatest during the first 18 weeks on treatment and then declines. The mechanism by which clozapine causes neutropenia is unknown and is not dose-dependent.

Two separate management algorithms are provided below, the first for patients in the general population, and the second for patients identified to have baseline neutropenia.

#### Clozapine Treatment and Monitoring in the General Patient Population (see Table 2)

- **Obtain a CBC, including the ANC value, prior to initiating treatment with clozapine** to ensure the presence of a normal baseline neutrophil count (equal to or greater than 1500/μL) and to permit later comparisons. Patients in the general population with an ANC equal to or greater than (+)1500/μL are considered within normal range (Table 2) and are eligible to initiate treatment. Weekly ANC monitoring is required for all patients during the first 6 months of treatment. If a patient’s ANC remains equal to or greater than 1500/μL for the first 6 months of treatment, monitoring frequency may be reduced to every 2 weeks for the next 6 months. If the ANC remains equal to or greater than 1500/μL for the second 6 months of continuous therapy, ANC monitoring frequency may be reduced to once every 4 weeks thereafter.

#### Table 2: Clozapine Treatment Recommendations Based on Absolute Neutrophil Count (ANC) Monitoring for the General Patient Population

<table>
<thead>
<tr>
<th>Normal range (&lt;1500/μL)</th>
<th>Treatment Recommendations</th>
<th>ANC Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Initiate treatment</td>
<td>• Discontinuation for reasons other than neutropenia</td>
<td>• Weekly from initiation to 6 months</td>
</tr>
<tr>
<td>• If treatment interrupted:</td>
<td></td>
<td>• Every 2 weeks from 6 to 12 months</td>
</tr>
<tr>
<td>- &lt;30 days, continue monitoring as before</td>
<td></td>
<td>• Monthly after 12 months</td>
</tr>
<tr>
<td>- &gt;30 days, monitor as if new patient</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Table 3: Patients with Benign Ethnic Neutropenia (BEN): Clozapine Treatment Recommendations Based on Absolute Neutrophil Count (ANC) Monitoring

<table>
<thead>
<tr>
<th>Normal BEN Range (Established ANC baseline &lt;1000/μL)</th>
<th>Treatment Recommendations</th>
<th>ANC Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Obtain at least two baseline ANC levels before initiating treatment</td>
<td>• Discontinuation of treatment for reasons other than neutropenia</td>
<td>• See Section 2.4</td>
</tr>
<tr>
<td>• If treatment interrupted:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- &lt;30 days, continue monitoring as before</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- ≥30 days, monitor as if new patient</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Confirm all initial reports of ANC less than 1500/μL with a repeat ANC measure-
2. If clinically appropriate
1. Confirm all initial reports of ANC less than 1500/μL with a repeat ANC measure-
[see Dosage and Administration (2.6)]. Consider reducing
[see Dosage and Administration (2.3)]. Use cautious titration and a divided dosage schedule to minimize the risk of serious
tolerated, to a target dose of 300 mg to 450 mg per day (administered in divided
total daily dose can be increased in increments of 25 mg to 50 mg per day, if well-
Treatment must begin at a maximum dose of 12.5 mg once daily or twice daily. The
mediated reflex bradycardia (NMRB).

5.3 Orthostatic Hypotension, Bradycardia, and Syncope

5.8 Eosinophilia

5.7 Increased Mortality in Elderly Patients with Dementia-Related Psychosis

5.6 Myocarditis and Cardiomyopathy

Myocarditis and cardiomyopathy have occurred with the use of clozapine. These reactions may be fatal. Discontinue clozapine and obtain a cardiac evaluation upon suspicion of myocarditis or cardiomyopathy. Generally, patients with a history of clozapine-associated myocarditis or cardiomyopathy should not be rechallenged with clozapine. However, if the benefit of clozapine treatment is judged to outweigh the potential risks of recurrent myocarditis or cardiomyopathy, the clinician may consider rechallenge with clozapine in consultation with a cardiologist, after a complete cardiac evaluation, and under close monitoring.

5.5 Increased Incidence of Myocarditis and Cardiomyopathy

The risk of myocarditis and cardiomyopathy in patients receiving clozapine who present with chest pain, dyspnea, persistent tachycardia at rest, palpitations, fever, flu-like symptoms, hypotension, other signs or symptoms of heart failure, or electrocardiographic findings (low voltages, ST-T abnormalities, arrhythmias, right axis deviation, and poor R wave progression), myocarditis most frequently presents within the first two months of clozapine treatment. Symptoms of myocarditis generally occur later than clozapine-associated myocarditis and usually after 8 weeks of treatment. However, myocarditis and cardiomyopathy can occur at any time during treatment. There is no strong scientific evidence to support a concomitant increase in the risk of cardiomyopathy and myocarditis in patients exposed to clozapine. If myocarditis or cardiomyopathy is suspected, consider discontinuation of clozapine, interruption of all other drugs that may be cardiotoxic, and cardiac evaluation and management.

5.4 Falls

Falls may cause somnolence, postural hypotension, and motor and sensory instability, which may lead to falls and, consequently, fractures or other injuries. For patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic treatment.

5.3 Orthostatic Hypotension, Bradycardia, and Syncope

Hypotension, bradycardia, syncope, and cardiac arrest have occurred with clozapine treatment. The risk is highest during the initial titration period, particularly with rapid dose-escalation. These reactions can occur with the first dose, at doses as low as 12.5 mg. These reactions can be fatal. The syndrome is consistent with neurally meditated reflex bradycardia (NMRB).

Treatment must begin at a maximum dose of 12.5 mg once daily or twice daily. The total daily dose can be increased in increments of 25 mg to 50 mg per day, if well-
tolerated, to a target dose of 300 mg to 450 mg per day (administered in divided
doses) by the end of 2 weeks. Subsequently, the dose can be increased weekly or twice weekly, in increments of up to 100 mg. The maximum dose is 900 mg per day. Use cautious titration and a divided dosage schedule to minimize the risk of serious cardiovascular reactions [see Dosage and Administration (2.3)]. Consider reducing the dose if hypotension occurs. When restarting patients who have had a brief interval off clozapine (i.e., 2 days or more since the last dose), re-initiate treatment at 12.5 mg once daily or twice daily [see Dosage and Administration (2.6)].

5.2 Clozapine REMS Program

Clozapine is only available through a restricted program under a REMS called the Clozapine REMS Program because of the risk of severe neutropenia.

Notable requirements of the Clozapine REMS Program include:

• Healthcare professionals who prescribe clozapine must be certified with the program by enrolling and completing training.
• Patients who receive clozapine must be enrolled in the program and comply with the ANC testing and monitoring requirements.
• Pharmacies dispensing clozapine must be certified with the program by enrolling and completing training and must only dispense to patients who are eligible to receive clozapine.

Further information is available at www.clozapinenems.com or 1-844-267-8678.

5.3 Orthostatic Hypotension, Bradycardia, and Syncope

Hypotension, bradycardia, syncope, and cardiac arrest have occurred with clozapine treatment. The risk is highest during the initial titration period, particularly with rapid dose-escalation. These reactions can occur with the first dose, at doses as low as 12.5 mg. These reactions can be fatal. The syndrome is consistent with neurally meditated reflex bradycardia (NMRB).

Treatment must begin at a maximum dose of 12.5 mg once daily or twice daily. The total daily dose can be increased in increments of 25 mg to 50 mg per day, if well-
tolerated, to a target dose of 300 mg to 450 mg per day (administered in divided
doses) by the end of 2 weeks. Subsequently, the dose can be increased weekly or twice weekly, in increments of up to 100 mg. The maximum dose is 900 mg per day. Use cautious titration and a divided dosage schedule to minimize the risk of serious cardiovascular reactions [see Dosage and Administration (2.3)]. Consider reducing the dose if hypotension occurs. When restarting patients who have had a brief interval off clozapine (i.e., 2 days or more since the last dose), re-initiate treatment at 12.5 mg once daily or twice daily [see Dosage and Administration (2.6)].

Use clozapine cautiously in patients with cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (e.g., concomitant use of antihypertensives, dehydration and hypovolemia).

5.4 Falls

Falls may cause somnolence, postural hypotension, and motor and sensory instability, which may lead to falls and, consequently, fractures or other injuries. For patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic treatment.

5.3 Orthostatic Hypotension, Bradycardia, and Syncope

Hypotension, bradycardia, syncope, and cardiac arrest have occurred with clozapine treatment. The risk is highest during the initial titration period, particularly with rapid dose-escalation. These reactions can occur with the first dose, at doses as low as 12.5 mg. These reactions can be fatal. The syndrome is consistent with neurally meditated reflex bradycardia (NMRB).

Treatment must begin at a maximum dose of 12.5 mg once daily or twice daily. The total daily dose can be increased in increments of 25 mg to 50 mg per day, if well-
tolerated, to a target dose of 300 mg to 450 mg per day (administered in divided
doses) by the end of 2 weeks. Subsequently, the dose can be increased weekly or twice weekly, in increments of up to 100 mg. The maximum dose is 900 mg per day. Use cautious titration and a divided dosage schedule to minimize the risk of serious cardiovascular reactions [see Dosage and Administration (2.3)]. Consider reducing the dose if hypotension occurs. When restarting patients who have had a brief interval off clozapine (i.e., 2 days or more since the last dose), re-initiate treatment at 12.5 mg once daily or twice daily [see Dosage and Administration (2.6)].
The median duration of exposure was 42 days for clozapine and chlorpromazine. The maximum daily dose range for the clozapine group demonstrated categorical increases from baseline in fasting glucose and lipids. The mean changes in fasting glucose concentration in the clozapine group were +11 mg/dL and +4 mg/dL, respectively. A higher proportion of the clozapine group demonstrated categorical increases from baseline in fasting glucose concentrations, compared to the chlorpromazine group. The clozapine doses were 100 to 900 mg per day (mean modal dose: 512 mg per day). The maximum chlorpromazine dose was 1800 mg per day (mean modal dose: 1029 mg per day). The median duration of exposure was 42 days for clozapine and chlorpromazine.

Prior to initiating treatment with clozapine, perform a careful physical examination, medical history, and concomitant medication history. Consider obtaining a baseline ECG and serum chemistry panel. Correct electrolyte abnormalities. Discontinue clozapine if the QTc interval exceeds 500 ms. If patients experience symptoms consistent with QT prolongation, treatment with medications that inhibit the metabolism of clozapine, and electrolyte abnormalities. Use caution when administering concomitant medications that prolong the QT interval or have intrinsic sympathomimetic activity. Baseline and periodic follow-up lipid evaluations in patients using clozapine, is recommended.

### 5.9 QT Interval Prolongation

QT prolongation, Torsades de Pointes and other life-threatening ventricular arrhythmias, cardiac arrest, and sudden death have occurred with clozapine treatment. When prescribing clozapine, consider the presence of additional risk factors for QT prolongation and serious cardiovascular reactions. Conditions that increase these risks include the following: history of QT prolongation, long QT syndrome, family history of long QT syndrome or sudden cardiac death, significant cardiac arrhythmia, recent myocardial infarction, uncompensated heart failure, treatment with other medications that cause QT prolongation, treatment with medications that inhibit the metabolism of clozapine, and electrolyte abnormalities.

### 5.10 Metabolic Changes

Atypical antipsychotic drugs, including clozapine have been associated with metabolic changes that can increase cardiovascular and cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain. While atypical antipsychotic drug use can produce some metabolic changes, each drug in the class has its own specific risk profile.

**Hyperglycemia and Diabetes Mellitus**

Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics including clozapine. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounding factors, the relationship between atypical antipsychotic use and hyperglycemia-related adverse reactions is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent, hyperglycemia-related adverse reactions in patients treated with the atypical antipsychotics. Precise risk estimates for hyperglycemia-related adverse reactions in patients treated with atypical antipsychotics are not available.

Patients with an established diagnosis of diabetes mellitus who are started on clozapine should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotics were discontinued; however, some patients had required continuation of anti-diabetic treatment despite discontinuation of the suspect drug. In a pooled data analysis of 8 studies in adult subjects with schizophrenia, the mean changes in fasting glucose concentration in the clozapine and chlorpromazine groups were +11 mg/dL and +4 mg/dL, respectively. A higher proportion of the clozapine group demonstrated categorical increases from baseline in fasting glucose concentrations, compared to the chlorpromazine group (Table 4). The clozapine doses were 100 to 900 mg per day (mean modal dose: 512 mg per day). The maximum chlorpromazine dose was 1800 mg per day (mean modal dose: 1029 mg per day). The median duration of exposure was 42 days for clozapine and chlorpromazine.

In a pooled data analysis of 10 studies in adult subjects with schizophrenia, clozapine treatment was associated with increases in serum total cholesterol. No data were collected on LDL and HDL cholesterol. The mean increase in total cholesterol was 13 mg/dL in the clozapine group and 15 mg/dL in the chlorpromazine group. In a pooled data analysis of 2 studies in adult subjects with schizophrenia, clozapine treatment was associated with increases in fasting serum triglyceride. The mean increase in fasting triglyceride was 71 mg/dL (54%) in the clozapine group and 39 mg/dL (35%) in the chlorpromazine group (Table 5). In addition, clozapine treatment was associated with categorical increases in serum total cholesterol and triglyceride, as illustrated in Table 6. The proportion of patients with categorical increases in total cholesterol or fasting triglyceride increased with the duration of exposure. The median duration of clozapine and chlorpromazine exposure was 45 days and 38 days, respectively. The clozapine dose range was 100 mg to 900 mg daily; the maximum chlorpromazine dose was 1800 mg daily.

**Table 4: Categorical Changes in Fasting Glucose Level in Studies in Adult Subjects with Schizophrenia**

<table>
<thead>
<tr>
<th>Laboratory Parameter</th>
<th>Category Change (at least once) from Baseline</th>
<th>Treatment Arm</th>
<th>N</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting Glucose</td>
<td>Normal (&lt;100 mg/dL) to High (≥126 mg/dL)</td>
<td>Clozapine</td>
<td>198</td>
<td>53(27)</td>
</tr>
<tr>
<td>Chlorpromazine</td>
<td>135</td>
<td>14(10)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Borderline (100 to 125 mg/dL) to High (≥126 mg/dL)</td>
<td>Clozapine</td>
<td>57</td>
<td>24(42)</td>
<td></td>
</tr>
<tr>
<td>Chlorpromazine</td>
<td>43</td>
<td>12(28)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Dyslipidemia**

Undesirable alterations in lipids have occurred in patients treated with atypical antipsychotics, including clozapine. Clinical monitoring, including baseline and periodic follow-up lipid evaluations in patients using clozapine, is recommended.

### Table 4: Categorical Changes in Fasting Glucose Level in Studies in Adult Subjects with Schizophrenia

<table>
<thead>
<tr>
<th>Treatment Arm</th>
<th>Baseline Total Cholesterol Concentration (mg/dL)</th>
<th>Change from Baseline mg/dL (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clozapine (N=334)</td>
<td>184</td>
<td>+13(7)</td>
</tr>
<tr>
<td>Chlorpromazine (N=185)</td>
<td>182</td>
<td>+15(8)</td>
</tr>
<tr>
<td></td>
<td>Baseline Triglyceride Concentration (mg/dL)</td>
<td>Change from Baseline mg/dL (%)</td>
</tr>
<tr>
<td>Clozapine (N=6)</td>
<td>130</td>
<td>+71(54)</td>
</tr>
<tr>
<td>Chlorpromazine (N=7)</td>
<td>110</td>
<td>+39(35)</td>
</tr>
</tbody>
</table>

### Table 6: Categorical Changes in Lipid Concentrations in Studies in Adult Subjects with Schizophrenia

<table>
<thead>
<tr>
<th>Laboratory Parameter</th>
<th>Category Change (at least once) from Baseline</th>
<th>Treatment Arm</th>
<th>N</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Cholesterol (random or fasting)</td>
<td>Increase by ≥40 mg/dL</td>
<td>Clozapine</td>
<td>334</td>
<td>111(33)</td>
</tr>
<tr>
<td>Chlorpromazine</td>
<td>185</td>
<td>46(25)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal (&lt;200 mg/dL) to High (≥240 mg/dL)</td>
<td>Clozapine</td>
<td>222</td>
<td>18(8)</td>
<td></td>
</tr>
<tr>
<td>Chlorpromazine</td>
<td>132</td>
<td>3(2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Borderline (200 to 239 mg/dL) to High (≥240 mg/dL)</td>
<td>Clozapine</td>
<td>79</td>
<td>30(38)</td>
<td></td>
</tr>
<tr>
<td>Chlorpromazine</td>
<td>34</td>
<td>14(41)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triglycerides (fasting)</td>
<td>Increase by ≥50 mg/dL</td>
<td>Clozapine</td>
<td>6</td>
<td>3(50)</td>
</tr>
<tr>
<td>Chlorpromazine</td>
<td>7</td>
<td>3(43)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal (&lt;150 mg/dL) to High (≥200 mg/dL)</td>
<td>Clozapine</td>
<td>4</td>
<td>0(0)</td>
<td></td>
</tr>
<tr>
<td>Chlorpromazine</td>
<td>6</td>
<td>2(33)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Borderline (≥150 mg/dL and &lt;200 mg/dL) to High (≥200 mg/dL)</td>
<td>Clozapine</td>
<td>1</td>
<td>1(100)</td>
<td></td>
</tr>
<tr>
<td>Chlorpromazine</td>
<td>1</td>
<td>0(0)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Weight Gain**

Weight gain has occurred with the use of antipsychotics, including clozapine. Monitor weight during treatment with clozapine. Table 7 summarizes the data on weight gain by the duration of exposure grouped from 11 studies with clozapine and active comparators. The median duration of exposure was 609, 728, and 42 days, in the clozapine, olanzapine, and chlorpromazine group, respectively.
Table 7: Mean Change in Body Weight (kg) by Duration of Exposure from Studies in Adult Subjects with Schizophrenia

<table>
<thead>
<tr>
<th>Metabolic Parameter</th>
<th>Exposure Duration</th>
<th>Clozapine (N=669)</th>
<th>Olanzapine (N=442)</th>
<th>Chlorpromazine (N=155)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n Mean</td>
<td>n Mean</td>
<td>n Mean</td>
<td>n Mean</td>
</tr>
<tr>
<td>Weight change from baseline</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 weeks (Day 11 to 17)</td>
<td>6 +0.9</td>
<td>3 +0.7</td>
<td>2 -0.5</td>
<td></td>
</tr>
<tr>
<td>4 weeks (Day 21 to 35)</td>
<td>23 +0.7</td>
<td>8 +0.8</td>
<td>17 +0.6</td>
<td></td>
</tr>
<tr>
<td>8 weeks (Day 49 to 63)</td>
<td>12 +1.9</td>
<td>13 +1.8</td>
<td>16 +0.9</td>
<td></td>
</tr>
<tr>
<td>12 weeks (Day 70 to 98)</td>
<td>17 +2.8</td>
<td>5 +3.1</td>
<td>0 0</td>
<td></td>
</tr>
<tr>
<td>24 weeks (Day 154 to 182)</td>
<td>42 -0.6</td>
<td>12 +5.7</td>
<td>0 0</td>
<td></td>
</tr>
<tr>
<td>48 weeks (Day 322 to 350)</td>
<td>3 +3.7</td>
<td>3 +13.7</td>
<td>0 0</td>
<td></td>
</tr>
</tbody>
</table>

Table 8 summarizes pooled data from 11 studies in adult subjects with schizophrenia demonstrating weight gain ≥7% of body weight relative to baseline. The median duration of exposure was 609, 728, and 42 days, in the clozapine, olanzapine, and chlorpromazine group, respectively.

Table 8: Proportion of Adult Subjects in Schizophrenia Studies with Weight Gain ≥7% Relative to Baseline Body Weight

<table>
<thead>
<tr>
<th>Weight Change</th>
<th>Clozapine</th>
<th>Olanzapine</th>
<th>Chlorpromazine</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>669</td>
<td>442</td>
<td>155</td>
</tr>
<tr>
<td>≥7% (inclusive)</td>
<td>236 (35%)</td>
<td>203 (46%)</td>
<td>13 (8%)</td>
</tr>
</tbody>
</table>

5.11 Neuroleptic Malignant Syndrome
Antipsychotic drugs including clozapine can cause a potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS). Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status, and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias). Associated findings can include elevated creatine phosphokinase (CPK), myoglobinuria, rhabdomyolysis, and acute renal failure. The diagnostic evaluation of patients with this syndrome is complicated. It is important to consider the presence of other serious medical conditions (e.g., severe neutropenia, infection, primary CNS pathology, central anticholinergic toxicity, extrapyramidal symptoms, and drug fever). The management of NMS should include (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, (2) intensive symptomatic treatment and medical monitoring, and (3) treatment of co-morbid medical conditions. There is no general agreement about specific pharmacological treatments for NMS. If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. NMS can recur. Monitor closely if restarting treatment with antipsychotics. NMS has occurred with clozapine monotherapy and with concomitant CNS-active medications, including lithium.

5.12 Hepatotoxicity
Severe, life threatening, and in some cases fatal hepatotoxicity including hepatic failure, hepatic necrosis, and hepatitis have been reported in patients treated with clozapine (see Adverse Reactions [5.2]). Monitor for the appearance of signs and symptoms of hepatotoxicity such as fatigue, malaise, anorexia, nausea, jaundice, bilirubinemia, coagulopathy, and hepatic encephalopathy. Perform serum tests for liver injury and consider permanently discontinuing treatment if hepatitis or transaminase elevations combined with other systemic symptoms are due to clozapine.

5.13 Fever
During clozapine therapy, patients have experienced transient, clozapine-related fever. The peak incidence is within the first 3 weeks of treatment. While this fever is generally benign and self-limited, it may necessitate discontinuing treatment. The fever can be associated with an increase or decrease in WBC count. Carefully evaluate patients with fever to rule out severe neutropenia or infection. Consider the possibility of NMS (see Warnings and Precautions [5.11]).

5.14 Pulmonary Embolism
Pulmonary embolism and deep-vein thrombosis have occurred in patients treated with clozapine orally disintegrating tablets. Consider the possibility of pulmonary embolism in patients with or without deep vein thrombosis, acute dyspnea, chest pain, or with other respiratory signs and symptoms. Whether pulmonary embolus and deep vein thrombosis can be attributed to clozapine or some characteristic(s) of patients is not clear.

5.15 Anticholinergic Toxicity
Clozapine has potent anticholinergic effects. Treatment with clozapine can result in CNS and peripheral anticholinergic toxicity. Use with caution in the presence of narrow-angle glaucoma, concomitant anticholinergic medications, prostatic hypertrophy, or other conditions in which anticholinergic effects can lead to significant adverse reactions. Treatment with clozapine can result in gastrointestinal adverse reactions, including constipation, intestinal obstruction, fecal impaction, and paralytic ileus. Such reactions can be fatal. Constipation should be initially treated by ensuring adequate hydration and use of ancillary therapy such as bulk laxatives. Consultation with a gastroenterologist is advisable in more serious cases.

5.16 Interference with Cognitive and Motor Performance
Clozapine can cause sedation and impairment of cognitive and motor performance. Caution patients about operating hazardous machinery, including automobiles, until they are reasonably certain that clozapine does not affect them adversely. These reactions may be dose-related. Consider reducing the dose if they occur.

5.17 Tardive Dyskinesia
Tardive dyskinesia (TD) has occurred in patients treated with antipsychotic drugs, including clozapine. The syndrome consists of potentially irreversible, involuntary, dyskinetic movements. The risk of TD and the likelihood that it will become irreversible are believed to increase with greater durations of treatment and higher total cumulative doses. However, the syndrome can develop after relatively brief treatment periods at low doses. Prescribe clozapine in a manner that is most likely to minimize the risk of developing TD. Use the lowest effective dose and the shortest duration necessary to control symptoms. Periodically assess the need for continued treatment. Consider discontinuing treatment if TD occurs. However, some patients may require treatment with clozapine despite the presence of TD. There is no known treatment for TD. However, the syndrome may remit partially or completely if treatment is discontinued. Antipsychotic treatment, itself, may suppress (or partially suppress) the signs and symptoms, and it has the potential to mask the underlying process. The effect of symptom suppression on the long-term course of TD is unknown.

5.18 Patients with Phenylketonuria
Phenylketonuric patients should be informed that clozapine orally disintegrating tablets contain phenylalanine (a component of aspartame). Each 25 mg, orally disintegrating tablet contains 2.8 mg phenylalanine. Each 100 mg, orally disintegrating tablet contains 11.2 mg phenylalanine.

5.19 Cerebrovascular Adverse Reactions
In controlled trials, elderly patients with dementia-related psychosis treated with some atypical antipsychotics had an increased risk (compared to placebo) of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack), including fatalities. The mechanism for this increased risk is not known. An increased risk cannot be excluded for clozapine or other antipsychotics or other patient populations. Clozapine should be used with caution in patients with risk factors for cerebrovascular adverse reactions.

5.20 Recurrence of Psychosis and Cholinergic Rebound after Abrupt Discontinuation of Clozapine
If abrupt discontinuation of clozapine is necessary (because of severe neutropenia or another medical condition, for example) (see Dosage and Administration [2.4], Warnings and Precautions [5.1]), monitor carefully for the recurrence of psychotic symptoms and adverse reactions related to cholinergic rebound, such as profuse sweating, headache, nausea, vomiting and diarrhea.

ADVERSE REACTIONS
The following adverse reactions are discussed in more detail in other sections of the labeling:
- Severe Neutropenia [see Warnings and Precautions [5.5]].
- Orthostatic Hypotension, Bradycardia, and Syncope [see Warnings and Precautions [5.3]].
- Falls [see Warnings and Precautions [5.4]].
- Seizures [see Warnings and Precautions [5.5]].
- Myocarditis and Cardiomyopathy [see Warnings and Precautions [5.6]].
- Increased Mortality in Elderly Patients with Dementia-Related Psychosis [see Warnings and Precautions [5.7]].
- Eosinophilia [see Warnings and Precautions [5.8]].
- QT Interval Prolongation [see Warnings and Precautions [5.9]].
- Metabolic Changes [Hyperglycemia and Diabetes Mellitus, Dyslipidemia, and Weight Gain] [see Warnings and Precautions [5.10]].
- Neuroleptic Malignant Syndrome [see Warnings and Precautions [5.11]].
- Hepatotoxicity [see Warnings and Precautions [5.12]].
- Fever [see Warnings and Precautions [5.13]].
- Pulmonary Embolism [see Warnings and Precautions [5.14]].
- Anticholinergic Toxicity [see Warnings and Precautions [5.15]].
- Interference with Cognitive and Motor Performance [see Warnings and Precautions [5.16]].
- Tardive Dyskinesia [see Warnings and Precautions [5.17]].
- Patients with Phenylketonuria [see Warnings and Precautions [5.18]].
- Cerebrovascular Adverse Reactions [see Warnings and Precautions [5.19]].
- Recurrence of Psychosis and Cholinergic Rebound after Abrupt Discontinuation [see Warnings and Precautions [5.20]].

6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The most commonly reported adverse reactions (≥5%) across clozapine clinical trials were: CNS reactions, including sedation, dizziness/vertigo, headache, and tremor; cardiovascular reactions, including tachycardia, hypotension, and syncope; autonomic nervous system reactions, including hyperperspiration, sweating, dry mouth, and visual disturbances; gastrointestinal reactions, including constipation and nausea; and fever. Table 9 summarizes the most commonly reported adverse reactions (≥5%) in clozapine-treated patients (compared to chlorpromazine-treated patients) in the pivotal, 6-week, controlled trial in treatment-resistant schizophrenia.

Table 9: Most Commonly Reported Adverse Reactions (≥5%) in Clozapine-Treated Patients Compared to Chlorpromazine-Treated Patients

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Clozapine (N=669)</th>
<th>Olanzapine (N=442)</th>
<th>Chlorpromazine (N=155)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight 6 weeks (Day 322 to 350)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥7% (inclusive)</td>
<td>236 (35%)</td>
<td>203 (46%)</td>
<td>13 (8%)</td>
</tr>
</tbody>
</table>

Clozapine can cause sedation and impairment of cognitive and motor performance. Caution patients about operating hazardous machinery, including automobiles, until they are reasonably certain that clozapine does not affect them adversely. These reactions may be dose-related. Consider reducing the dose if they occur.
Table 9: Common Adverse Reactions (≥5%) in the 6-Week, Randomized, Chlorpromazine-Controlled Trial in Treatment-Resistant Schizophrenia

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>Chlorpromazine (N=142) (%)</th>
<th>Chlorpromazine (N=142) (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sedation</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>Tachycardia</td>
<td>11</td>
<td>11</td>
</tr>
<tr>
<td>Constipation</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>Dizziness</td>
<td>16</td>
<td>16</td>
</tr>
<tr>
<td>Hypertension</td>
<td>38</td>
<td>38</td>
</tr>
<tr>
<td>Fever (hyperthermia)</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Hypersalivation</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Hypertension</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Headache</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Nausea/Vomiting</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>Dry mouth</td>
<td>20</td>
<td>20</td>
</tr>
</tbody>
</table>

Table 10 summarizes the adverse reactions reported in clozapine-treated patients at a frequency of 2% or greater across all clozapine studies (excluding the 2 year InterSePT™ Study). These rates are not adjusted for duration of exposure.

Table 10: Adverse Reactions (≥2%) Reported in Clozapine-treated Patients (N=842) Across All Clozapine Studies (excluding the 2 year InterSePT™ Study)

<table>
<thead>
<tr>
<th>Body System</th>
<th>Clozapine Adverse Reaction</th>
<th>Percentage of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central Nervous System</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drowsiness/Sedation</td>
<td>39</td>
<td></td>
</tr>
<tr>
<td>Dizziness/Vertigo</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Tremor</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Syncope</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Disturbed Sleep/Nightmares</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Restlessness</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Hypokinesia/Akinesia</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Seizures (convulsions)</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Rigidity</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Akathisia</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Confusion</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Insomnia</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tachycardia</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>Hypotension</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Constipation</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Abdominal Discomfort/Heartburn</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Nausea/Vomiting</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Vomiting</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Diarrhea</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Urogenital</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary abnormalities</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Autonomic Nervous System</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salivation</td>
<td>31</td>
<td></td>
</tr>
<tr>
<td>Sweating</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Dry mouth</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Visual disturbances</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Skin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rash</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Hemic/Lymphmic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukopenia/Decreased WBC/Neutropenia</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Miscellaneous</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Weight Gain</td>
<td>4</td>
<td></td>
</tr>
</tbody>
</table>

1 Rate based on population of approximately 1700 exposed during premarket clinical evaluation of clozapine.

Table 11 summarizes the most commonly reported adverse reactions (≥10% in the clozapine or olanzapine group) in the InterSePT™ Study. This was an adequate and well-controlled, two-year study evaluating the efficacy of clozapine relative to olanzapine in reducing the risk of suicidal behavior in patients with schizophrenia or schizoaffective disorder. The rates are not adjusted for duration of exposure.

Table 11: Incidence of Adverse Reactions in Patients Treated with Clozapine or Olanzapine in the InterSePT™ Study (≥10% in the clozapine or olanzapine group)

<table>
<thead>
<tr>
<th>Adverse Reactions</th>
<th>Clozapine N=479 % Reporting</th>
<th>Olanzapine N=477 % Reporting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salivary hypersecretion</td>
<td>48%</td>
<td>6%</td>
</tr>
<tr>
<td>Somnolence</td>
<td>46%</td>
<td>25%</td>
</tr>
<tr>
<td>Weight increased</td>
<td>31%</td>
<td>56%</td>
</tr>
<tr>
<td>Dizziness (excluding vertigo)</td>
<td>27%</td>
<td>12%</td>
</tr>
<tr>
<td>Constipation</td>
<td>25%</td>
<td>10%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>20%</td>
<td>33%</td>
</tr>
<tr>
<td>Nausea</td>
<td>17%</td>
<td>10%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>17%</td>
<td>9%</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>14%</td>
<td>9%</td>
</tr>
</tbody>
</table>

Dystonia

Class effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of clozapine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Central Nervous System

Delirium, EEG abnormal, myoclonus, paresthesia, possible cataplexy, status epilepticus, obsessive compulsive symptoms, and post-discontinuation cholinergic rebound adverse reactions.

Cardiovascular System

Atrial or ventricular fibrillation, ventricular tachycardia, QT interval prolongation, Torsades de Points, myocardial infarction, cardiac arrest, and periorbital edema.

Endocrine System

Pseudopheochromocytoma

Gastrointestinal System

Acute pancreatitis, dysphagia, salivary gland swelling.

Hepatobiliary System

Cholestasis, hepatitis, jaundice, hepatotoxicity, hepatic steatosis, hepatic necrosis, hepatic fibrosis, hepatic cirrhosis, liver injury (hepatic, cholestatic, and mixed), and liver failure.

Immune System Disorders

Angioedema, leukocytoclastic vasculitis.

Urogenital System

Acute interstitial nephritis, nocturnal enuresis, priapism, and renal failure.

Skin and Subcutaneous Tissue Disorders

Hypersensitivity reactions: photosensitivity, vasculitis, erythema multiforme, skin pigmentation disorder, and Stevens-Johnson Syndrome.

Musculoskeletal System and Connective Tissue Disorders

Myasthenic syndrome, rhabdomyolysis, and systemic lupus erythematosus.

Respiratory System

Aspiration, pleural effusion, pneumonia, lower respiratory tract infection.

Hemic and Lympthic System

Mild, moderate, or severe leukopenia, agranulocytosis, granulocytopenia, WBC decreased, deep vein thrombosis, elevated hemoglobin/hematocrit, erythrocyte sedimentation rate (ESR) increased, sepsis, thrombocytosis, and thrombocytopenia.

Vision Disorders

Narrow-angle glaucoma.

Miscellaneous

Cretine phosphokinase elevation, hyperuricemia, hyponatremia, and weight loss.

7 DRUG INTERACTIONS

7.1 Potential for Other Drugs to Affect Clozapine

Clozapine is a substrate for many cytochrome P450 isozymes, in particular CYP1A2, CYP2A6, and CYP2D6. Use caution when administering clozapine orally disintegrating tablets concomitantly with drugs that are inducers or inhibitors of these enzymes.

CYP1A2 Inhibitors

Concomitant use of clozapine orally disintegrating tablets and CYP1A2 inhibitors can increase plasma levels of clozapine, potentially resulting in adverse reactions. Reduce the clozapine orally disintegrating tablets dose to one-third of the original dose when clozapine orally disintegrating tablets are coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, or enoxacin). The clozapine orally disintegrating tablets dose should be increased to the original dose when coadministration of strong CYP1A2 inhibitors is discontinued [see Dosage and Administration (2.7), Clinical Pharmacology (12.3)].

Moderate or weak CYP1A2 inhibitors include oral contraceptives and caffeine. Monitor patients closely when clozapine orally disintegrating tablets are coadministered with these inhibitors. Consider reducing the clozapine orally disintegrating tablets dosage if necessary [see Dosage and Administration (2.7)].
**CLOZAPINE ORALLY DISINTEGRATING TABLETS**

**CYP2D6 and CYP3A4 Inhibitors**

Concomitant treatment with clozapine orally disintegrating tablets and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions [see Clinical Pharmacology (12.3)]. Use caution and monitor patients closely when using such inhibitors. Consider reducing the clozapine orally disintegrating tablets dose [see Dosage and Administration (2.7)].

**CYP1A2 and CYP3A4 Inducers**

Concomitant treatment with drugs that induce CYP1A2 or CYP3A4 can decrease the plasma concentration of clozapine, resulting in decreased effectiveness of clozapine orally disintegrating tablets. Tobacco smoke is a moderate inducer of CYP1A2. Strong CYP3A4 inducers include carbamazepine, phenytoin, St. John's wort, and rifampin. It may be necessary to increase the clozapine orally disintegrating tablets dose if used concomitantly with inducers of these enzymes. However, concomitant use of clozapine orally disintegrating tablets and strong CYP3A4 inducers is not recommended [see Dosage and Administration (2.7)].

Consider reducing the clozapine orally disintegrating tablets dosage when discontinuing coadministered enzyme inducers; because discontinuation of inducers can result in increased clozapine plasma levels and an increased risk of adverse reactions [see Dosage and Administration (2.7)].

**Drugs that Cause QT Interval Prolongation**

Use caution when administering concomitant medications that prolong the QT interval or inhibit the metabolism of clozapine. Drugs that cause QT prolongation include: specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, thioridazine, mesoridazine, droperidol, and pimozide), specific antibiotics (e.g., erythromycin, gatifloxacin, clarithromycin, sparfloxacin), Class IIA antiarrhythmics (e.g., quinidine, procainamide) or Class III antiarrhythmics (e.g., amiodarone, sotalol), and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, procanol or tacrolimus) [see Warnings and Precautions (5.9)].

**8.2 Potential for Clozapine to Affect Other Drugs**

Concomitant use with other drugs metabolized by CYP2D6 can increase levels of these CYP2D6 substrates. Use caution when coadministering clozapine with other drugs that are metabolized by CYP2D6. It may be necessary to use lower doses of such drugs than usually prescribed. Such drugs include specific antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecaïnide, and encainide).

**8 USE IN SPECIFIC POPULATIONS**

**8.1 Pregnancy**

**Risk Summary**

There are no adequately or well-controlled studies of clozapine in pregnant women. Reproductive studies have been performed in rats and rabbits at doses up to 0.4 and 0.9 times, respectively, the maximum recommended human dose (MRHD) of 900 mg/day on a mg/m² body surface area basis. The studies revealed no evidence of impaired fertility or harm to the fetus due to clozapine. Because animal reproduction studies are not always predictive of human response, clozapine orally disintegrating tablets should be used during pregnancy only if clearly needed.

**Clinical Considerations**

Consider the risk of exacerbation of psychosis when discontinuing or changing treatment with antipsychotic medications during pregnancy and postpartum. Consider early screening for patients planning to or currently treated with antipsychotic medications [see Warnings and Precautions (5.10)]. Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. Monitor neonates for symptoms of agitation, hyperactivity, hypotonia, tremor, somnolence, respiratory distress, and feeding difficulties. The severity of complications can vary from self-limited symptoms to some neonates requiring intensive care unit support and prolonged hospitalization.

**Animal Data**

In embryofetal developmental studies, clozapine had no effects on maternal parameters, litter sizes, or fetal parameters when administered orally to pregnant rats and rabbits during the period of organogenesis at doses up to 0.4 and 0.9 times, respectively, the MRHD of 900 mg/day on a mg/m² body surface area basis. In peri/postnatal developmental studies, pregnant female rats were administered clozapine over the last third of pregnancy and until day 21 postpartum. Observations were made on fetuses at birth and during the postnatal period; the offspring were allowed to wean normally and mature. Clozapine caused a decrease in maternal body weight but had no effects on litter size or body weights of either F1 or F2 generations at doses up to 0.4 times the MRHD of 900 mg/day on a mg/m² body surface area basis.

**8.3 Nursing Mothers**

Clozapine is present in human milk. Because of the potential for serious adverse reactions in nursing infants from clozapine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

**8.4 Pediatric Use**

Safety and effectiveness in pediatric patients have not been established.

**8.5 Geriatric Use**

There have not been sufficient numbers of geriatric patients in clinical studies utilizing clozapine to determine whether those over 65 years of age differ from younger subjects in their response to clozapine.

Orthostatic hypotension and tachycardia can occur with clozapine treatment [see Boxed Warning and Warnings and Precautions (5.3)]. Elderly patients, particularly those with compromised cardiovascular functioning, may be more susceptible to these effects.

**10 OVERDOSE**

**10.1 Overdose Experience**

The most commonly reported signs and symptoms associated with clozapine overdose include: sedation, delirium, coma, tachycardia, hypotension, respiratory depression or failure; and hypersalivation. There are reports of aspiration pneumonia, cardiac arrhythmias, and seizures. Fatal overdoses have been reported with clozapine, generally at doses above 2500 mg. There have also been reports of patients recovering from overdoses well in excess of 4 g.

**10.2 Management of Overdose**

For the most up-to-date information on the management of clozapine overdose, contact a certified Regional Poison Control Center (1-800-222-1222). Telephone numbers of certified Regional Poison Control Centers are listed in the Physicians’ Desk Reference®, a registered trademark of PDR Network. Establish and maintain an airway; ensure adequate oxygenation and ventilation. Monitor cardiac status and vital signs. Use general symptomatic and supportive measures. There are no specific antidotes for clozapine.

In managing overdose, consider the possibility of multiple-drug involvement.

**11 DESCRIPTION**

Clozapine Orally Disintegrating Tablets, an atypical antipsychotic drug, are a tricyclic dibeno[d]azepine derivative, 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[a,e] [1,4] diazepine. The structural formula is:

![Clozapine Structure](https://example.com/clozapine_structure.png)

Clozapine, USP is available as yellow, orally disintegrating tablets of 25 mg and 100 mg for oral administration without water. Clozapine Orally Disintegrating Tablets may be chewed. Each orally disintegrating tablet contains clozapine, USP, equivalent to 25 mg and 100 mg.

The active component of Clozapine Orally Disintegrating Tablets is clozapine, USP. The remaining components are aspartame powder, colloidal silicon dioxide, crospovidone, magnesium stearate, mannitol, microcrystalline cellulose, peppermint flavor, sodium stearyl fumarate and xylitol.

**THIS PRODUCT CONTAINS ASPARTAME AND IS NOT INTENDED FOR USE BY INFANTS. PHENYLKETONURICS: CONTAINS PHENYLALANINE**

**CLINICAL PHARMACOLOGY**

**12.1 Mechanism of Action**

The mechanism of action of clozapine is unknown. However, it has been proposed that the therapeutic efficacy of clozapine in schizophrenia is mediated through antagonism of the dopamine type 2 (D₂) and the serotonin type 2A (5-HT₂A) receptors. Clozapine orally disintegrating tablets also act as an antagonist at adrenergic, cholinergic, histaminergic and other dopaminergic and serotonergic receptors.

**Cloned Pharmacodynamics**

Clozapine demonstrated binding affinity to the following receptors: histamine H₁ (Ki 1.1 nM), adrenergic α₁a (Ki 1.6 nM), serotonin 5-HT₄ (Ki 4 nM), serotonin 5-HT₃ (Ki 5.4 nM), muscarinic M₁ (Ki 6.2 nM), serotonin 5-HT₆ (Ki 6.3 nM), serotonin 5-HT₂C (Ki 9.6 nM), dopamine D₁ (Ki 24 nM), adrenergic α₂a (Ki 90 nM), serotonin 5-HT₂ (Ki...
**12.3 Pharmacokinetics**

Absorption

In man, clozapine tablets (25 mg and 100 mg) are equally bioavailable relative to a clozapine solution. Clozapine orally disintegrating tablets are bioequivalent to Clozaril® (clozapine) tablets, a registered trademark of Novartis Pharmaceuticals Corporation. Following a dosage of 100 mg b.i.d., the average steady-state peak plasma concentration was 413 ng/mL (range: 132 to 854 ng/mL), occurring at the average of 2.3 hours (range: 1 to 5 hours) after dosing. The average minimum concentration at steady-state was 168 ng/mL (range: 45 to 574 ng/mL), after 100 mg b.i.d. dosing. A comparative bioequivalence/bioavailability study was conducted in 32 patients (with schizophrenia or schizoaffective disorder) comparing clozapine orally disintegrating tablets to 2 × clozapine orally disintegrating 100 mg tablets (the approved reference product) under fasted conditions. The study also evaluated the effect of food and chewing on the pharmacokinetics of the 200 mg tablet. Under fasted conditions, the mean AUC0-24 of clozapine for the 200 mg tablets were equivalent to those of the 2 × 100 mg tablets. The mean Cmax,ss of clozapine for clozapine orally disintegrating tablets was 85% that for 2 × 100 mg clozapine orally disintegrating tablets. This decrease in Cmax,ss for clozapine orally disintegrating 200 mg tablets is not clinically significant. For clozapine orally disintegrating 200 mg tablets, food significantly increased the Cmax,ss of clozapine by 21%. However, this increase is not clinically significant. The mean AUC0-24, Cmax,ss, and Tmax of clozapine under fasted conditions were equivalent to those under fasted conditions. Food delayed clozapine absorption by 1.5 hours, from a median Tmax of 2.5 hours under fasted conditions to 4 hours under fed conditions.

In a food-effect study, a single dose of clozapine orally disintegrating tablets 12.5 mg was administered to healthy volunteers under fasting conditions and after a high-fat meal. When clozapine orally disintegrating tablets were administered after a high-fat meal, the Tmax,ss of clozapine and its active metabolite, desmethylclozapine, decreased by approximately 20%, compared to administration under fasting conditions, while the AUC values were unchanged. This decrease in Tmax,ss is not clinically significant. Therefore, clozapine orally disintegrating tablets can be taken without regard to meals.

Distribution

Clozapine is approximately 97% bound to serum proteins. The interaction between clozapine and other highly protein-bound drugs has not been fully evaluated but may be important [see Drug Interactions (7)].

Metabolism and Excretion

Clozapine is almost completely metabolized prior to excretion, and only trace amounts of unchanged drug are detected in the urine and feces. Clozapine is a substrate for hepatic cytochrome P450 enzymes, particularly CYP2D6. Approximately 75% of a clozapine dose is excreted in the urine and 25% in the feces. The metabolic pathway involves hydroxylation, N-demethylation, and N-oxide formation to form a variety of active metabolites. The primary metabolic pathway is CYP2D6-dependent. Approximately 70% of a clozapine dose is excreted in the urine as glucuronide conjugates of unchanged drug and metabolites. Less than 1% of the dose is excreted in the urine as parent drug. Greenblatt et al. [1998] reported that the elimination half-life of clozapine was approximately 15 hours in healthy volunteers and approximately 20 hours in patients with schizophrenia.

Pharmacological testing has shown the desmethyl metabolite (norclozapine) to have only limited activity, while the hydroxylated and N-oxide derivatives were inactive. The mean elimination half-life of clozapine after a single 75 mg dose was 8 hours (range: 4 to 12 hours), compared to a mean elimination half-life of 12 hours (range: 4 to 66 hours), after achieving steady state with 100 mg twice daily dosing. A comparison of single-dose and multiple-dose administration of clozapine demonstrated that the elimination half-life increased significantly after multiple dosing relative to that after single-dose administration, suggesting the possibility of concentration-dependent pharmacokinetics. However, at steady state, approximately dose-proportional changes with respect to AUC (area under the curve), peak, and minimum clozapine plasma concentrations were observed after administration of 37.5, 75, and 150 mg twice daily.

Drug-Drug Interaction Studies

Fluvoxamine

A pharmacokinetic study was conducted in 16 schizophrenic patients who received clozapine under steady-state conditions. After coadministration of fluvoxamine for 14 days, mean trough concentrations of clozapine and its metabolites, N-demethyloclozapine and clozapine N-oxide, were elevated about three-fold compared to baseline steady state concentrations. Paroxetine, Fluoxetine, and Sertraline

In a study of schizophrenic patients (n=14) who received clozapine under steady-state conditions, coadministration of paroxetine produced only minor changes in the levels of clozapine and its metabolites. However, other published reports describe modest elevations in the levels of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.

Clozapine ORALLY DISINTEGRATING TABLETS

**CLOZAPINE ORALLY DISINTEGRATING TABLETS**

**CLOZAPINE ORALLY DISINTEGRATING TABLETS**

95 nM), serotonin 5-HT2a (K 120 nM), dopamine D1 (K 160 nM), dopamine D2 (K 270 nM), dopamine D3 (K 454 nM), and dopamine D4 (K 555 nM). Clozapine causes little or no prolactin elevation.

Clinical electroencephalogram (EEG) studies demonstrated that clozapine increases delta and theta activity and slows dominant alpha frequencies. Enhanced synchronization occurs. Sharp wave activity and spike and wave complexes may also develop. Patients have reported an intensification of dream activity during clozapine therapy. REM sleep was found to be increased to 85% of the total sleep time. In these patients, the onset of REM sleep occurred almost immediately after falling asleep.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

No carcinogenic potential was demonstrated in long-term studies in mice and rats at doses up to 0.3 times and 0.4 times, respectively, the maximum recommended human dose (MRHD) of 900 mg/day on a mg/m² body surface area basis.

Mutagenesis

Clozapine was not genotoxic when tested in the following gene mutation and chromosomal aberration tests: the bacterial Ames test, the in vitro mammalian V79 in Chinese hamster cells, the in vitro unscheduled DNA synthesis in rat hepatocytes or the in vivo micronucleus assay in mice.

Impairment of Fertility

Clozapine had no effect on any parameters of fertility, pregnancy, fetal weight or postnatal development when administered orally to male rats 70 days before mating and to female rats for 14 days before mating at doses up to 0.4 times the MRHD of 900 mg/day on a mg/m² body surface area basis.

14 CLINICAL STUDIES

14.1 Treatment-Resistant Schizophrenia

The efficacy of clozapine in treatment-resistant schizophrenia was established in a multicenter, randomized, double-blind, active-controlled (chlorpromazine) study in patients with a DSM-III diagnosis of schizophrenia who had inadequate responses to at least 3 different antipsychotics (from at least 2 different chemical classes) during the previous 1 year. The antipsychotic therapies must have been non-responding. The antipsychotic dosages must have been equivalent to or greater than 1000 mg per day of chlorpromazine for a period of at least 6 weeks, each without significant reduction of symptoms. There must have been no period of good functioning within the preceding 5 years. Patients must have had a baseline score of at least 45 on the investigator-rated Brief Psychiatric Rating Scale (BPRS). On the 18-item BPRS, 1 indicates the absence of symptoms, and 7 indicates severe symptoms; the maximum potential total BPRS score is 126. At baseline, the mean BPRS score was 61. In addition, patients must have had a score of at least 4 on at least two of the following four individual BPRS items: conceptual disorganization, suspiciousness, hallucinatory behavior, and unusual thought content. Patients must have had a Clinical Global Impressions – Severity Scale score of at least 4 (moderately ill).

In the prospective, lead-in phase of the trial, all patients (N=305) initially received single-blind treatment with haloperidol (the mean dose was 61 mg per day) for 6 weeks. More than 80% of patients completed the 6 week trial. Patients with an insufficient response to haloperidol (n=268) were randomized to double-blind treatment with clozapine (N=126) or chlorpromazine (N=142). The maximum daily clozapine dose was 900 mg; the mean daily dose was >600 mg. The maximum daily chlorpromazine dose was 1800 mg; the mean daily dose was >1200 mg. The primary endpoint was treatment response, predefined as a decrease in BPRS score of at least 20% and either (1) a CGI-S score of ≤3 (mildly ill), or (2) a BPRS score of ≤35, at the end of 6 weeks of treatment. Approximately 88% of patients from the clozapine and chlorpromazine groups completed the 6-week trial. At the end of six weeks, 30% of the clozapine group responded to treatment, and 4% of the chlorpromazine group responded to treatment. The difference was statistically significant (p <0.001). The mean change in total BPRS score was -16 and -5 in the clozapine and chlorpromazine group, respectively; the mean change in the 4 key BPRS item scores was -5 and -2 in the clozapine and chlorpromazine group, respectively; and the mean change in CGI-S score was -1.2 and -0.4, in the clozapine and chlorpromazine group, respectively; the mean change was -5 and -2 in the clozapine and chlorpromazine group, respectively; and the mean change in CGI-S score was -1.2 and -0.4, in the clozapine and chlorpromazine group, respectively. These changes in the clozapine group were statistically significantly greater than in the chlorpromazine group (p <0.001 in each analysis).

14.2 Recurrent Suicidal Behavior in Schizophrenia or Schizoaffective Disorder

The effectiveness of clozapine in reducing the risk of recurrent suicidal behavior was assessed in the International Suicide Prevention Trial (InterSePT™), a trademark of Novartis Pharmaceuticals Corporation). This was a prospective, open-label, active-controlled, multicenter, international, parallel-group comparison of clozapine (Clozaril®) versus olanzapine (Zyprexa®, a registered trademark of Eli Lilly and Company) in 956 patients with schizophrenia or schizoaffective disorder (DSM-IV) who were judged to be at risk for recurrent suicidal behavior. Only about one-fourth of the patients (27%) were considered moderate to severe suicidal ideation within one week prior to the baseline evaluation.

To enter the trial, patients must have met one of the following criteria:

- They had attempted suicide within the three years prior to their baseline evaluation.
- They had been hospitalized to prevent a suicide attempt within the three years prior to their baseline evaluation.
- They demonstrated moderate-to-severe suicidal ideation with a depressive component within one week prior to their baseline evaluation.
- They demonstrated moderate-to-severe suicidal ideation accompanied by command hallucinations to do self-harm within one week prior to their baseline evaluation.

Dosing regimens for each treatment group were determined by individual investigators and were individualized by patient. Dosing was flexible, with a dose range of 200 to
CLOZAPINE ORALLY DISINTEGRATING TABLETS

900 mg/day for clozapine and 5 to 20 mg/day for olanzapine. For the 956 patients who received clozapine or olanzapine in this study, there was extensive use of concomitant psychotropics: 84% with antipsychotics, 65% with anxiolytics, 53% with antidepressants, and 28% with mood stabilizers. There was significantly greater use of concomitant psychotropic medications among the patients in the olanzapine group. The primary efficacy measure was time to (1) a significant suicide attempt, including a completed suicide, (2) hospitalization due to imminent suicide risk, including increased level of surveillance for suicidality for patients already hospitalized; or (3) worsening of suicidality severity as demonstrated by "much worsening" or "very much worsening" from baseline in the Clinical Global Impression of Severity of Suicidality as assessed by the Blinded Psychiatrist (CGI-SS-BP) scale. A determination of whether or not a reported event met criterion 1 or 2 above was made by the Suicide Monitoring Board (SMB), a group of experts blinded to patient data. A total of 980 patients were randomized to the study and 956 received study medication. Sixty-two percent of the patients were diagnosed with schizophrenia, and the remainder (38%) were diagnosed with schizoaffective disorder. Only about one-fourth of the total patient population (27%) was identified as "treatment-resistant" at baseline. There were more males than females in the study (61% of all patients were male). The mean age of patients entering the study was 37 years of age (range 18 to 69). Most patients were Caucasian (71%), 15% were Black, 1% were Asian, and 13% were classified as being of "other" races. Patients treated with clozapine had a statistically significant longer delay in the time to recurrent suicidal behavior in comparison with olanzapine. This result should be interpreted only as evidence of the effectiveness of clozapine in delaying time to recurrent suicidal behavior and not a demonstration of the superior efficacy of clozapine over olanzapine. The probability of experiencing (1) a significant suicide attempt, including a completed suicide, or (2) hospitalization because of imminent suicide risk, including increased level of surveillance for suicidality for patients already hospitalized, was lower for clozapine patients than for olanzapine patients at Week 104: clozapine 24% versus olanzapine 32% (p=0.03). (Figure 1). Patients treated with clozapine had a statistically significant longer delay in the time to recurrent suicidal behavior in comparison with olanzapine. This result should be interpreted only as evidence of the effectiveness of clozapine in delaying time to recurrent suicidal behavior and not a demonstration of the superior efficacy of clozapine over olanzapine. The probability of experiencing (1) a significant suicide attempt, including a completed suicide, or (2) hospitalization because of imminent suicide risk, including increased level of surveillance for suicidality for patients already hospitalized, was lower for clozapine patients than for olanzapine patients at Week 104: clozapine 24% versus olanzapine 32% (p=0.03). (Figure 1).

Figure 1: Cumulative Probability of a Significant Suicide Attempt or Hospitalization to Prevent Suicide in Patients with Schizophrenia or Schizoaffective Disorder at High Risk of Suicidality

- Clozapine patients had a statistically significant longer delay in the time to recurrent suicidal behavior in comparison with olanzapine. This result should be interpreted only as evidence of the effectiveness of clozapine in delaying time to recurrent suicidal behavior and not a demonstration of the superior efficacy of clozapine over olanzapine. The probability of experiencing (1) a significant suicide attempt, including a completed suicide, or (2) hospitalization because of imminent suicide risk, including increased level of surveillance for suicidality for patients already hospitalized, was lower for clozapine patients than for olanzapine patients at Week 104: clozapine 24% versus olanzapine 32% (p=0.03). (Figure 1).

10 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

25 mg Yellow, round, flat-faced, beveled-edge, uncoated tablet. Debossed with I2 on one side and plain on the other side. Available in bottles of 100 (NDC 0093-5417-01) and cartons of 48 tablets for Institutional Use Only (8x6 blister cards) (NDC 0093-5417-64).

100 mg Yellow, round, flat-faced, beveled-edge, uncoated tablet. Debossed with I2 on one side and plain on the other side. Available in bottles of 100 (NDC 0093-5419-01) and cartons of 48 tablets for Institutional Use Only (8x6 blister cards) (NDC 0093-5419-64).

16.2 Storage and Handling

Store Clozapine Orally Disintegrating Tablets at 20° to 25°C (68° to 77°F). (See USP Controlled Room Temperature.) Protect from moisture. Keep in a sealed blister until time of use. This unit-dose package is non child-resistant. Clozapine Orally Disintegrating Tablets contain phenylalanine (a component of aspartame) [see Warnings and Precautions (5.18)].

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

25 mg Yellow, round, flat-faced, beveled-edge, uncoated tablet. Debossed with I2 on one side and plain on the other side. Available in bottles of 100 (NDC 0093-5417-01) and cartons of 48 tablets for Institutional Use Only (8x6 blister cards) (NDC 0093-5417-64).

100 mg Yellow, round, flat-faced, beveled-edge, uncoated tablet. Debossed with I2 on one side and plain on the other side. Available in bottles of 100 (NDC 0093-5419-01) and cartons of 48 tablets for Institutional Use Only (8x6 blister cards) (NDC 0093-5419-64).

16.2 Storage and Handling

Store Clozapine Orally Disintegrating Tablets at 20° to 25°C (68° to 77°F). (See USP Controlled Room Temperature.) Protect from moisture. Keep in a sealed blister until time of use. This unit-dose package is non child-resistant. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Clozapine Orally Disintegrating Tablets must remain in the original package until used by the patient. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).

Drug dispensing should not ordinarily exceed a weekly supply. If a patient is eligible for ANC testing every 2 weeks, then a 2-week supply of Clozapine Orally Disintegrating Tablets can be dispensed. If a patient is eligible for ANC testing every 4 weeks, then a 4-week supply of Clozapine Orally Disintegrating Tablets can be dispensed. Dispensing should be contingent upon the ANC testing results.

17 PATIENT COUNSELING INFORMATION

Discuss the following issues with patients and caregivers:

- **Severe Neuroleptic**: Instruct patients (and caregivers) beginning treatment with clozapine about the risk of developing severe neuropenia and infection.